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ABSTRACT 
Distinct HIV variants occur at the genital mucosa compared to in blood, which may similarly 
result in differences in HIV T cell responses. There have been no studies of the maturational 
status of HIV -specific T cells present at the female genital mucosa. This study aimed to 
characterise HIV -specific cervical immune responses and to determine if compartmentalized 
immune responses occur in chronic HIV infection by comparing the characteristics of T cells 
at the cervical mucosa to those in blood. This was achieved by evaluating the anti-HIV 
responsiveness of cervical and systemic T cells in vitro using HIV -specific T cell clones. 
Thirty five HIV+ women with CD4 counts >300/ul were included in this study. All of these 
women were screened for HIV Gag-specific responsiveness using IFN -1 ELlS pot and a panel 
of 9 high HIV -1 Gag responders was identified. T cell clones were generated from paired 
cervical and blood specimens from each of these 9 donors. A total of 74 blood clones (out of 
566 plated) and 51 cervical T cell clones (out of the 454 plated) were selected from the 9 
donors. Of these 12174 blood derived clones and 2/51 cervical clones were HIV-specific. 
Significantly fewer HIV -specific cervical T cell clones were generated than blood-derived 
clones. None of the T cell clones expanded sufficiently during in vitro culture to allow finer 
mapping of HIV Gag epitope responses. I investigated the maturational status of these 
cervix-derived and blood-derived T cell clones by assessing CD57 expression of these cells. 
CD57 is a terminal differentiation or exhaustion marker on T cells that has been associated 
with a lack of proliferative capacity or replicative senescence. While no difference was 
observed in the expression of the exhaustion marker CD57 between matched blood and 
cervical T cells ex vivo, CD57 expression was significantly higher in cervical clones than 
blood clones cultured for similar periods of time. CD57 expression was significantly higher 
in cervical T cell clones than cervical T cells assessed directly ex vivo, a trend not observed 
in blood-derived T cells. It is clear that further investigation into T cell proliferative and 
functional impairment is necessary to improve the efficiency of the generation of HIV-
specific T cell clones by limiting dilution in order to determine if compartmentalisation of 
HIV -specific T cell responses exists between the blood and the cervix. This is the first study 
to have investigated CD57 expression of cervical-derived T cells particularly under 
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2 
t.J.t. Int roductio n 
~lore than two decodes lum:' passed since the fil'Sl reported inc idents of Acquired 
Immunodeficient") Syndromo: (AIDS). In 1983. the causative ~'CIl1 of AIDS, the Human 
ImmuoOOcfieicOl:')' lIil1.ls (1II11) .... llS identified (Barre-SinotlSSi 1'1 ul.. 1983). Tod(lY. the 
number ofpcople infel;\ed .... ith J 1111 has reoched pandemic proportions. In 2005 ne:uly 40 
mIllion people were Jiving ..... iLh 1111/. with (lbout 25-mill ion oflhis I IIII -illfcctcd population 
hailing from sub-Sahan:m Africa (Figure l.IA: UNAIDS Repon on lhe Global AIOS 
epidemic. 20(6). Ofthcse l i lli-infected ind il'iduals. women outnumbero:d men by 2-fold 
(Figure 1. 1 B). Since women arc particularly I'UJncrablc 10 hetemse:uml lransmissiorl of 
11111 for a number of reasons illCluding .socioeconomic. biological and physiological factors 
(UNFPA. 2007). thc-se Slahstics clear!} emphasise the need \0 prt:I'enl 11111 infcetion al the 
sit(: o f sc1Cual uansmissioll in ..... omen. the ilCllital mucosa. and t~ impol'Ulllce of stud} ing 
immune respooses at thi s sil(: 
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Figure 1.1. A ~Iobal l it'\\' or 111 11 in rrclion. ZOOS .. (A) 11111 prevalence accord ing 10 
gc"Ogmphie region.. The dar'-er colours indicille regions with thc higher prevalence whereas 
thc lighter colours indicate rcgiOrlS with the lower internationa l prc\"alencc. Abou t 15-34% 
of the 40 million people in il'Ctcd with 11111 worldwide hailed from Sub·Saharan Africa.. (8 ) 
11111 prevalence W.) is described by b'<: ndcr in various Africl\l1 countries (200 1-2005). In 
most countries. the number of IlllI ·infect"d women outnumbered the II1I1 .. infcctcd men 
(uduptcd from UNAIDS. 2(06). 
J 
The impJrtn~r of the mlJ(:osal immune system in HIV infection nnd pathogenesis Ilas only 
ItCrmly been !'I:cognized. The mucosal system not only plays a fundaIDt'ntal role m mv 
pathogenesis by 5<'rving as a portal o f entry during betero5<'xual imercours<' (Kozlowski 
and Neutra, 2003; Neutra ~I (II , 1996) but also as tile p,,--dominarH site of virus "'plication 
and CD4 ' T cell depletion (Veazey 1.'1 (II .. 1998), This bas led S('\'C1'1iII investrgalOts to 
ackno\lledgc thnt althou~ I IlV hM a SY~1emic pluasc ofinf,,'I;'tion that is easily ~ble: 
it is largely a di$Case of the mucosal immune .!)'St~·m (Vell7.ey ~nd LackJlt'r. 2005). TIlC' 
interaction or tile rnucosnl immune ~yStern from the female genital mlJ(:O$a with HIV is tho: 
foc:us ofLhl: eum:nt study. 
1.1.2. mv subtype C 
Thr;.'(' groups of HIV-I M\'e been id,'ntifird: groups M. N and 0: Figure 1.2: Thomsoo 1'1 
111 .• 2002). The most prevalent b'l'OUP. M. is sulxlividrd into right subl:)'f)eS (M)ers 1'1 aI 
1992, 1994). H[V subtype C is the pre&min.:un t)pe foond in ArriCll and Mi_: IIIV 
sub type B in Nurth Am~7ica and Europe; \lhilr IIIV subtype, A and 0 commonly affIXt 
Africa (Hemdaar rl 1,1 .. 2006). I-IIV subtype C IICcoon\!i for S~ of nil HIV infections 
wotld\lide and is currmtly the predominant subtype affecting South Africa (I'igull: 1.3~ 
HcIDt'laar 1'1 ai, 2006; van HarmclCTI ('f al., 1999: Novitsky ('I 11/ .• 2(02), The I IIV subtype 
C .,pidcmics nre eommonly defined by high prc\OIlenee niles in !he aduh population 
(liemelaar 1'/ 11/ . 20(6). with high likelihoods of \mical uansmission (Renjifo n a/ . 
2001). hi~ \'iT1l1 loads (Neilson n al., 1999). pll:fercmially infecting cells bearing the 
chemokine receptor CCRS (RS-tropic; (Abebc 1'1 (II .• 1999). alxi by displaymg gll:al viral 




Fi!:u rr 1.1. Ph) lo~rnrl ir tr"CC' of ~Ifflro pnnllu ~ len til iruus I IIV and S I V t p7.. Three 
groups of IIIV_ I have been identified (groups M, N und 0) \lith the moSt pll:I'alcnl group 
(M) being subdivUkd inlo right diSliocl subtypes (A. 8. C, D. F, G. 11. and J), I IiV is 
clo5<'ly related to SIV. in parliculnr 10 SIV 5pC\!ific 10 ChlmpllM:CS (SIVcpz: adapted from 
Kuiken 1'1 aI . 1999), 
4 
Figu re- 1.3, (;Ioblll distribution of 111 \'·1 subt}pft lind rt'combinan ls in 2~, The 
number of infections caU5ed b) 111\'·1 subt)pe5 and recombinanlJi IIR' represented as a 
proportion o f the global .otlll number of individuuls h~ ,ng wllh mY.1 (adapted from 
li1:mc:laar N ai , 20(6) 
t , t ,3, HIV- I ge nomi c organiLation and structure 
TJxo IIIV ~nome is compnsed of 9 I,ICIK'S encoding .anous necessary $Irul: lural (Gag, Pol 
and En_ : I.ociw, (996), ac:cessor)' (Net: Yir, Ypu and Vpr. Anderson and I lopt, 200-1) and 
regulatOI) (fat and Re": Addo rt til. 2001: Ikll ,.f aI,. 2007) proteins (rt'\' iewed in ~'rud, 
1998). A summary of 1he armngcn'Cnl and fUI"ll"tion of each of IhC:!.t 9 gtoeS is sho"" in 
Figure I 4. The BITllnScn1o!nt ofthesc gene prodOCI$ in the mat~ HIV particle IS sIlo .... n in 
Figure 1.5. The.-!;Qg gene pn.xlucts are m;ponsibk for the formation oflhc . iral cBPliid. 
nucleocapsid and matrix proteins (Melamed e( of , 2QO.:1). Processing of the i'm' ~11C' 
produclJi resullJi in the surface glycoprotein gp120 and U'lltISITIrn1branc protein £P41 
(Kiauto "( oC 1998: Lu j"f of, 1995). IIlV pol enoodc:s fOt" the enzymc:s (Protell5C. re\";:rsc 
tmnscriptase and integrase) nccessat). for the completion of the "ira] replicatioo cycle ir the 
host cell (Luci"". (996), The regulatOr) proteins Tat and Rn- arc essent ial for transcription 
of the "iml genorn.e and regulation of late gene expression rcspecth'e ly (Molirn. 1989: Kao 
rt 01 .. 1987). The accessory proteins Vpu. Vpr. Vif and Nef arc eollecthely responsibk fOf 
the infectivity. reproduction and pathogencsisoflJle virus (EmeTmll1l and Malirn. 1998) 
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figure 1.4. Onn'je'" of the organisa tion of tht' HI V prm'irus grnomt'. The illustration 
summarises lhe anungemelll of lhc 9 HIV genes ~nd [he ftmCliollS of (heir 15 prolein 
products (lOkcn from Green and Peu:rl in. 2002; Sheehy 1'1 al .. 2002). Also depicted are the 
long temlinal repeal regions flanking the proviml genom .. al the 5' and 3' ends. 
o ,_ .. t, .. ~_ jp&l.'p.S t ~q 
Figun' I .S. S~h~m l tic represenla tion of Ih(' I rra nge n1 ('nl o r HIV. I g('ne p roducts in 
the malu re ,·irion . The IIIV-! virion. indicating the approxilJ1llle location of Gag proteins. 
the Env gl}'eoprolcins. and the pol-cneoded enz)'IOCS IN. RT. and PR. Colours in the \'irion 
eOtTCspond lO the localion ofthc proteins in Ihe Gag precursor (adapted from Frecd, 1998). 
6 
1lIe l'tII! sene provides Inc basic SllUClural elements oflhe \ irus aod eomprises the /I'I:"lri)( 
protein (MA) p 17; capsid prolein (CA) p24: nuckocapsid (Ne) p7: p6 in\'Ol wd in late \'iraJ 
as.ca: mbl) (Freed, 2002 ): and splicer proteins p2 and pI Ilhich sep!lI'lIle CA from NC and 
NC from p6 n:spccli\ely (MeJ'\'is el uf. , 1988; Figure I ,S: Figure 1,61. 
p2 p1 
HIV Gag • NC p6 
Fi~urt' 1,6, Ar nlngemcnt or I II V Gag d~\'lIi!e p rollll(t~ ... ithin th., Gag pu l~ prOlein 
(adapted from GOnlinger. 2001 ~ 
TIle p24 capsid protein is the 1l1O~ cOIlSeJ'\'ed of 1111 Gag regions (Buseyne el ul .. 1992). 
ScH:ral Sludies ha.ve sbo ... n that point mumtions in this gene tC'5U1t in the prevention of 
\-irion assembly (Liang eI 1.1/ .• 2003: Rl;'icin tt ut 1995: Srinil!lSlkum.'ll' tl 111 .• 1995) and 
carl) stages of infection (Tang t/ at 2003). The maln~ protdn (pIn domain is required 
for lirion assembl) as \lcll PS for membrnne binding (OrlO rl a/.. 1999, 2000) nnd the 
nucleocapsid protein (p7) is n:quired for birding to \liral RNA (Zhang t l a/ , 1997) and 
subsequent rntttpSidation during I'irion 11.SllI:mbly (Dorfml1ll " 01 . 1993). As a n:suh. the 
~'Ug gene harbours highly co~J'\'cd n:gions (OUSC:)TIC rl (lJ.. 1992). For eXllmple, a highly 
cO!lSlo'l"\'cd gJ)'cioc ":sidue #I'\CS as a myriSl yhllion silc al the N II:rminus of p l7 (000 t l 
al.. 2000): 20 cO!\$CI'\'cd residuc:s ill p24 are responsible for !he h)drophobic core of the 
protein (Gamble rl aL 1997); a conSC'J'\'ed ljnc Iini;CT mlllif in p7 bUlds RNA (Zhang t l (1/" 
1997), Recentl) , 11 residues al !he C-Il:rminus of p24 ... -c:re ilkflti fied as beini highl) 
SC'nsllh'e 10 point mutatIOnS and, as a resu lt. in,oll·cd in the rom:ct l\SSCmbl} al!d discl'large 
of I II V \ irions (Melamed t l o/.. 20(4), As a resu lt. numerous studil'$ Il/'e focused on lhe 
de"c1opmem of drugs and ''IIccines directed at these: con!lel'\'ed regions in IIIV Gag 
(Oole-sta tl uI 2005; Ondondo e/ ai" 2006: Xu '1 ai , 200& Tober) e/ aI, 2006; Ta"el tl 
1" , 2001). 
1.1.4. The lIl V-spccific cellulat' immune rcsponse 
1. 1.4. 1. T he inlporta nce of C[)8~ T cc lls ill thc control o f tll V 
A IlUtnbc:r of studies rum: pm,idcd stlUf\g c\idcncc 10 suggest thaI C1l8- T lymphoc)1e 
responses (c)1okinc and 1)1ic) an: imponant in cOfloolling l'iral replication in IIIV-infec ted 
indh iduals. l lumtm su>d ics have sho ... n th.:it in the carly phase of infection. the J'IIl.'sence of 
HIV-specific CDS- T Iymphocytc and 001 CD4' 'I ce lls or IlCUtrnhzing IlDtibod} responscs 
are lemporall ) lISSOCialcd wi th the dec line of plasma viremia (Figure 1.1; Appay t l til . 
1 
2002; 8orrOl' ('/oL 1994 ; Gray i'I II/" ]999: KOllp I!I al .. 1995). Strong H1V+!o-p<:dfic CD8' 
c)'IO!Oxk T I)mphocytc (CTL) rl!sponSl:S arc maintained in long term non·progre'!SOrs 
(Miguelcs £'1 al .. 2002; iktts £'1 al .. 20(6) and have also b..-Crl demonstrated in several 
cohons or highly exposed yet persiStCl1 i!y semnegati, '\' individuals (Kaul 0:1 al .. 2000. 2001 ; 
Rowland·Jones ('I al . 1997. 1998). Most convincingly. CD8' lymphocyte depletion studies 
in SIV·infected mllClIqlles have shown greater "ira] replication WId more rapid disease 







"', ymplo m.>lIe 
P~ ... 
r-" - - - --
••• 
-, ' .. , 
" I 
,. ..... , ,-
t , '/ 
'-
...... -. " \. 
, , , ,, ___ _ :J •• , 
• " , " , , ... 
, ,'--, -,:--.:-~:-,:,:-,C.:-~::--.:":-~::-C,:,:-.C':-':':-'M::-C"C.'!'"~,:-,,,. 
•••••••• C D~' r <ells 
____ Unl Ab 
HIV Clio- ____ HlVvnlload 
figu~ 1.7. T~mPOI"1lI a~~ociation be tw«n dcrlinc in III V , -iralillad and emergence of 
Ul Vo-S IK'cific C llS T cd l number (but nOI C 1l4 T ccll IIr neutralizing antibody 
concentrations) durin ],: the cnUniC (I f HIV infect ion. HIV primarily infects CD4' T cells 
and clmmcteristically results in CD4' T ~ell depletion. The presence of CDS' T 
l)mphocytes is tcmporally associated '\ith lhe decline of pll\SlTla ,; remia (adapted from 
Alimonli CIIII. , 2003). 
Nt1l1l<' rous scudies 1m,'': described the \'lI'Perb>ence of HlV variants with specific mutations in 
the pre<:ise b'Coomic regions IUfgetcd by CDS' cn. that kad to the escape of that viral 
vurian t from en. dctet:lion. This suggests selectivc immWle pressure is placed on the , -irus 
b) CTLs (Borrow el al., 1997: GO\.I ldcr fI lit . 1997). FlInhermore. certllin Human 
I.eukocyte Antigen (I-I LA) alleles have been observed to co=late with HIV discas.:: control 
Of progression. suggesting "DrYing degrees of presel1lation and funct ional activ ity by CD8+ 
T lymphocytes (Knslow el al .• 1996; Carrington I!I 01., 1999). Not a!l potential escape 
mutations in IIIV gene products arc hamdess to viral fitness. For example. more <'scope 
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variams IIrc observed in regions to1cmting more sequence variability (Ner. Tat. Em) than in 
more conserved regions (Gag; Johllson et ul., 1993: Yusim 1.'1 ul. , 2002). illY Gag p2-1 is 
the mOSI conscrved region of the gag gene (Buscync tl al., 1992). en.. escape mUl.3nts in 
Ihis region have bt."cD observed 10 occur as a resulT of mUl.3tion in only a single site 
(Bal"Ouch el al., 1002: Gou1dcr 1'1 III .. 1997). mostlikdy due: to a high COSI \0 viml fitness 
on greatcr s.."""qucnce variation. In comrast. escape mutants deseribed from Ncr and Env 
regions (regions with generally more tolerance for sequence variability than Gag p24) have 
betln obscT\'i;d 10 arise at multiple silcs (Evans 1'1 ul.. [999: Uorrow f't al.. 1997). 
1.1.4.2. Corrt' lat~ of protection in the control of HI V inrection 
Numerous studies have provided confl icting data on the ilS~ialion between HIY vira l load 
and the CDS' T cell response. While somc studies have dcmonslr.ued no din.-ct cOrn'!ation 
between oWTIll 1 IIIY· I·specifie !FN.), produc.tion by CDS' T cells and pillsnm viremia or 
CD4 ' T cell counts (Addo 1'1 al .• 2003: Edwards 1" al., 20(2). others corlfirm thaI CDS' T 
cell resporlscs direc ted against HIY Gag ha,'C the ability to reduce viral set-point and "re 
therefore impol1am in cOrltl"OllIng lilY infection (ratite 1'1 01 .• 2002: Ocldmacher ('I a/ .• 
2007). Scveml studies have demonstmti;d inverse eom:btions bcC\l,'eom viml load and the 
magnitude aoo breadth of HIV Gag pN-specitic CfL resPOrlSCS (Kkpicla rl a/.. 2007; 
Maselllola el al .. 2004; Novitsky eI al .. 2003: Edwards ('I lIl .. 2002). FunhemlOre, targeting 
of certain HIY Gag epitopes, paniculorly wilhin the highly conserved p24 region , can drive 
strung sck-ction pressure on the virus. evidenced by lower viremia (Kiepicla ~I al .. 2007: 
Maninez-I'icado ('I al . 2(06). Rerem studics have emphasi7-cd the importance of 
polyfuTlC tionality in T cell function (the abili ty of T cells to set::rete multiple cytokines and 
perform multiplc funct ions) in the eontro! of pen;islcnt lilY and other chronic viral 
infec tions (Casazza el al .• 2006: BeltS III 01. , 2006). Betts ('I uf (2006) showed that the 
abi lity of thes;: HJV-specific CfLs 10 exhibit multip le functions· not JUS! IFN·)' production 
alone - hest predicted control ofvir~ 1 replication. 
1.1 .... 2. Th e im [Jllrt :.l nee of lIIucosal a ssocia l l' d ly mpho id tissue in HTV 
tra n s missio n anti pathngcncs is 
It is ' .... idel> acccptl'"tl that HI\' infection is essentially a disease of the mucosa.! tmmune 
system (Vea",(C)' and Lackner. 2005; Joim.'iOu and KaUT. 2005). Thc major route of sexual 
transmission of my is through mucosal exposure to cell rree and cell·associated virus, 
primnrily althe mucosa lining the rectum arid vagina (Ncutra III (II. 1996; K07JO\\,-sJ.;j and 
NC lIt m. 2003). and it is the mucosa of the gastrointcslinal tmct thaI servcs as the primary 
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site of virus replication (Veazey et al., 1998; Brenchley et al., 2004; Mehandru et al., 
2004). The target cells for HIV infection, effector memory CCR5+ CD4+ T cells, are 
abundant in the mucosa, predominantly in the intestine, but are rare in the peripheral blood 
(Veazey et al., 2000; Brenchley et al., 2004; Mehandru et aI., 2004; Li et al., 2005). As a 
result, large scale depletion of these susceptible cells has been observed in the mucosa of 
the vagina (Veazey et al., 2003), lung (Vajdy et al., 2001) and predominantly in the 
gastrointestinal tract (Mehandru et al., 2004; Brenchley et al., 2004), before significant 
depletion within the periphery and lymph nodes (Mattapallil et al., 2005; Li et al., 2005; 
Brenchley et al., 2004; Mehandru et aI., 2004). About 30 - 60% of intestinal CD4+ T cells 
are infected during acute HN infection. Of this infected CD4+ T cell population, about 60 
- 80% is depleted within 4 days of infection (Mattapallil et al., 2005; Li et al., 2005). Since 
CD4+ T cells are essentially responsible for generating help for immune responses (Noelle 
and Snow, 1990; Meyaard et al., 1994; Fogelman et al., 2000; Autran et al., 1997) and are 
therefore an integral component of the mucosal immunological barrier against invading 
pathogens, it is likely that their extensive depletion significantly affects the proper function 
of the mucosal barrier (Johnson and Kaur, 2005). In light of evidence of the mucosal 
system being the fundamental site of entry and virus replication, strategies to develop 
effective AIDS vaccines and therapies are increasingly focusing on stimulating mucosal 
immune responses (Belyakov and Berzofsky, 2004; Lekkerkerker et al., 2004; Ranasinghe 
et al., 2007; de Souza et al., 2007). 
1.1.4.4. HIV -specific CTL responses at the mucosa 
A number of studies have demonstrated that the mucosal compartment is important in 
controlling HN infection (Bomsel et al., 2007; Kaul et al., 2000; Belyakov et al., 1998). In 
a murine model ofHN transmission, Belyakov et al (1998) showed that it is mucosal CTL 
responses and not systemic responses that are necessary to prevent HIV -1 transmission. 
Similarly in macaques, SN -specific CTL responses at the rectal mucosa were shown to be 
important for protection against intra-rectal challenge with SIV (Murphey-Corb et al., 
1999). In humans, HIV-specific CTL have been identified in various mucosal 
compartments including the cervicovaginal mucosa (Musey et al., 1997, 2003), semen 
(Quayle et al., 1998), rectum (Shacklett et al., 2000b), human breast milk (Sabbaj et al., 
2002); and even in the mucosa of the lung (Plata et al., 1987). However, inherent technical 
difficulties associated with sampling of mucosal tissues have limited the understanding of 
mucosal HIV-specific cellular immune responses in humans. 
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1.1.4.5. HIV -specific CTL responses at the female genital tract 
Several studies in both humans and non-human primates have presented evidence for HIV-
specific CTL responses in the genital mucosa (Lohman et al., 1995; Reynolds et al., 2005; 
Kaul et al., 2000,2003; Shacklett et al., 2000b; lbarrondo et al., 2005; Quayle et al., 2007). 
SIV -specific CTL response in the genital tract of female macaques after intravaginal 
inoculation of SIV was first documented by Lohman et al. (1995). More recently, Stevceva 
et al. (2004) identified SIV Gag-specific CD8+ T cells in samples from the rectum, colon, 
jejunum, and vagina of most of their SIV-infected female macaques (Stevceva et al., 2004). 
These cells expressed the activation marker CD69 and produced IFN-y (Stevceva et al., 
2004). Although a robust SIV -specific CD8+ T lymphocyte response in primate 
reproductive tissues is clearly demonstrable, Reynolds et al. (2005) showed that this strong 
response was only observed after the peak in SIV replication and was of insufficient 
magnitude at early time points to prevent infection and systemic dissemination. 
There have been a number of studies which have described HIV -specific T cell responses 
in chronically HIV -infected women (Musey et al., 1997; 2003; Kaul et al., 2000; lbarrondo 
et al., 2005; Shacklett et al., 2000b; Quayle et al., 2007). Musey et al. (1997) identified 
human HIV -specific cervical T cells that mediated HLA class I -restricted HIV -specific 
cytolysis. The cytolytic activity of the cervical T cells was directed to one or more epitopes 
within the env-, gag-, or pol-encoded HIV proteins (Musey et al., 1997). The HIV -specific 
CD8+ CTL isolated from the genital mucosal were shown to produce perf orin and favour 
the granule exocytosis method of destruction of HIV -infected target cells rather than the 
apoptotic FaslFas-ligand mechanism (Musey et al., 2003). Furthermore, cervical HIV-
specific CTL have been shown to secrete IFN-y (Kaul et al., 2000). 
HIV -specific CTL have also been identified in the genital tract of highly exposed yet mv 
seronegative individuals (Kaul et al., 1998, 2000, Shacklett et al., 2000). The presence of 
HIV -specific CD8+ T lymphocyte responses was demonstrated in the cervix of HIV -1-
resistant Kenyan sex workers in the absence of detectable systemic HIV infection (Kaul et 
al., 2000). In a follow-up study, it was concluded that a major factor associated with late 
seroconversion and HIV infection was a break from sex work, implying that continuous 
antigenic exposure was needed to maintain the CTL response at the cervix (Kaul et al., 
2000). 
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There is still much not understood about mucosal immunity in humans; primarily because 
of difficulties associated with sampling mucosal tissues, isolating T lymphocytes from 
these samples, and generating mucosal T lymphocytes in culture (Musey et al., 2003). Most 
knowledge of the HIV -specific immune response is therefore based on studies in blood. 
1.1.5. Organization of the female genital tract 
The lower genital tract in women is comprised of four distinct regions: (1) the keratinised 
introitus (vaginal opening), (2) the vaginal mucosa, (3) the ectocervix, and (4) the 
endocervix (Figure 1.8, Pudney et al., 2005). The abrupt transition between the ectocervix 
and endocervix, known as the transformation zone, contains the largest number of 
lymphocytes in the female lower genital tract (Edwards et al., 1985). Dendritic cells and 
their specialized mucosal counterparts, Langerhans' cells, appear equally in the endo- and 
ectocervix as well as vaginal opening regions but not in the vaginal mucosa (Pudney et al., 
2005). Other immune cells such as macrophages and granulocytes have also been identified 
in the cervix and vagina (White et al., 1997). High concentrations of CD8+ cells (ClL and 
natural killer cells) and antigen-presenting cells in the ectocervix and transformation zone 
suggest the possibility of these sites being the predominant locations for the induction of 
effector CTL responses in the lower genital tract (Pudney et al., 2005). The endocervix also 
contains numerous IgA + and I~ cells, rendering it the predominant site for local humoral 
immune responses (Kutteh, 1999). 
1.1.5.1. Early events during sexual transmission of HI V to women 
Intact vaginal epithelium can serve as an efficient barrier to viral penetration (Shattock and 
Moore, 2003; Miller et al., 2005). Furthermore, cervical mucous can strengthen this 
defence by trapping virions in the vaginal lumen (Maher et al., 2005; Miller et al., 2005). 
Nevertheless, the presence of large quantities of dendritic cells (DCs) and intraepithelial 
lymphocytes at the transformation zone (Edwards and Morris, 1985; Pudney et al., 2005) 
has highlighted the possibility of this being the primary site of HIV transmission as both of 
these cell types have been implicated in HIV infection (Hu et al., 2000; Spira et al., 1996). 
Although the predominant mode of infection remains to be determined, several different 
routes of HIV infection have been demonstrated. HIV can cross the cervicovaginal barrier 
either as a result of epithelial damage (from trauma-related abrasions or lesions due to 
sexually-transmitted infections); transcytosis across an intact epithelial barrier (Bomsel, 
1997); or by capture and transfer by intraepithelial dendritic cells (Lee et al., 2001). The 
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lauer method of infection IS fac ilitated by dendritic cells that cross the eervicol'aginJI 
barrkr 
Figure 1.8. Organization of the fcma l ~ genital In d . ll1c lower fema le genital tmet is 
comprised of the vaginal opening (not shown here). the l'agiMI mucosa (not mown ilen:). 
the ecto- or ellocen.h. and the endocervi.,. Shown arc the columnar ecll~ of the endoccn.·ill. 
tile squamous cells ofthc ex lo- or elloccrvill. Wld the squamocolumnar junctions (SCI) and 
tnulsfonnation mn.: between th.. ectocervix and endoccrvi., (from: 
http;!I",ww .m~·n:kmedieu.uomlp[!/u.<;/hcpldiseascmodulc¥hp\'dllUllural-hjslorv .jspl 
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and peripheral tissues. Innate and adaptive host defences (left column) are directed at the 
different stages to prevent transmission and contain infection (from Pope and Haase, 2003). 
either as a result of epithelial damage (from trauma-related abrasions or lesions due to 
sexually-transmitted infections); transcytosis across an intact epithelial barrier (Bomsel, 
1997); or by capture and transfer by intraepithelial dendritic cells (Lee et al., 2001). The 
latter method of infection is facilitated by dendritic cell surface-expression of CD4, 
chemokine coreceptor, and C-type lectin receptors. R5 viruses are selectively transmitted 
(Meng et al., 2002). Several studies have suggested that DC-bound virions traversing the 
epithelial layer could either infect and complete their replication cycle within DC or be 
liberated from the DC and infect CD4-bearing T helper cells, macrophages and dendritic 
cells (McDonald et al., 2003; Pope et al., 1994, 1995). Once HIV has gained entry, virus is 
transported via the afferent lymphatics to CD4+ T helper cell-rich lymph nodes to further 
disseminate the infection (Miller et al., 2005). Figure 1.9 illustrates the early events during 
sexual transmission and acute infection in the female genital tract. 
1.1.6. Compartmentalization and HIV genetic diversity in the 
genital tract 
Studies of viral evolution between and within HIV subtypes often compare the envelope 
gene sequence, as its high degree of genetic variation is commonly observed in its 
product's (gp120) ability to determine cell tropism (Fisher et al., 1988; O'Brian et al., 
1990; Shioda et al., 1991) and escape from the host immune response (Borrow et al., 1997; 
Goulder et al., 1997; Wei et al., 2003). Comparisons of HIV envelope genes in blood and 
in the genital secretions of HIV -infected women identified genetic differences as a result of 
the insertion of new potential glycosylation sites in the variable regions of the envelope 
glycoprotein (Overbaugh et al., 1996), a property known to affect the immunogenicity of 
gp120 (Wei et al., 2003). Furthermore, the HIV isolates from the genital mucosa were 
closer related to only a minor subset of PBMC variants (Poss et al., 1995; 1998). This 
result highlights the possibility that distinct viral species may arise independently in 
response to unique tissue-specific selection pressures (such as availability of CD4+CCR5+ 
or CD4+CXCR4+ bearing cells) or as a result of the selective migration of one or more 
HIV -infected cells between the blood and mucosa, followed by the local expansion and 
evolution of the virus in that region (Poss et al., 1998). These reports therefore emphasise 
the importance of understanding immune control mechanisms at the site of heterosexual 
transmission. 
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In addition, Ellerbrock et al. (2001) showed clearly that cellular replication of HIV -1 does 
occur in vaginal secretions. They demonstrated by direct sequencing of HIV-l gp120 
envelope in matched blood plasma, vaginal lavage samples and cervical mucous that the 
major species of cell-free HIV -1 in cervical secretions were more similar to each other than 
those found in blood plasma (Ellerbrock et al., 2001). Analysis of the HIV-l drug 
resistance-associated region of HIV-l pol in cell-free HIV RNA in matched plasma and 
vaginal lavage samples showed that a drug resistance-associated mutation in plasma may 
not predict the same in vaginal secretions, and therefore suggested that viral replication 
between the two compartments is largely independent (Ellerbrock et al., 2001). This is 
further supported by the observation that replicating proviral populations and quasispecies 
in the female genital tract are less genetically diverse and divergent than those in blood 
(Sullivan et al., 2005). A study of full-length RNA genomes derived from the genital tract 
and blood in the same individuals further supported the concept of viral 
compartmentalisation (Philpott et al., 2005). HIV-l recombinants composed of alternating 
viral sequences of the distinct viral populations were identified in the blood and genital 
tract of the same HIV -infected woman, suggesting that intra-patient recombination between 
different anatomical compartments could be another major source of HIV -1 evolution 
(Philpott et al., 2005). 
Taken together, the increasing body of evidence for compartmentalisation of HIV-l 
between blood and the genital tract suggests the possibility of a similar 
compartmentalisation of HIV -specific immune responses. Since blood-derived viral 
populations may not mirror those in the genital tract, further study on local mucosal virus 
populations and the HIV -specific immune response is crucial for the design of vaccines and 
drugs to prevent sexual transmission ofHIV. 
1.1.7. Compartmentalisation of HI V-speci tic T cell responses 
The mounting evidence for the independent evolution of viral populations between the 
genital mucosa and the periphery (Poss et al., 1995; Overbaugh et al., 1996, Ellerbrock et 
al., 2001) increases the likelihood of the concomitant compartmentalisation of the HIV-
specific immune response. There is however little evidence to support this hypothesis. 
Musey et al. (1997) observed cytolytic activity by cervical T cells to various HIV-l 
epitopes. Furthermore the HIV -1 epitope specificities and HLA class I restriction patterns 
ofCTL clones from the cervix and blood of the same individual were similar (Musey et al., 
1997). This implied that the CTL repertoire is common in those two anatomically distinct 
15 
compartments of HI V-infected women (Musey et al., 1997). In addition, the HIV-specific 
CTL response was directed to a narrower spectrum of HIV -epitopes in the mucosa than the 
blood (Musey et al., 1997). This observation could be attributed to, among others, the 
possible diversity in the virus population from genital mucosa and blood (Poss et al., 1995). 
Subsequently, Musey et al. (2003) sequenced the V~ repertoire of the T cell receptors of 
CD8+ CTL from the blood, cervix, rectum and semen of mv -I-infected individuals to 
compare clonally derived lymphocyte populations between the compartments. They found 
identical HIV -I-specific CTL clones in different compartments in the same individual 
suggesting that some blood and mucosal mv -specific CTL can be of common origin and 
can traffic between the blood and the mucosa (Musey et al., 2003). There is increasing 
evidence to support the occurrence of overlapping HIV-I epitope specificities between 
blood and mucosal CTL (Kaul et al., 2000; Ibarrondo et al., 2005). In a recent comparison 
of blood and mucosal CTL responses across the full HIV genome, concordant responses 
between the cervix and blood compartments was observed in 85.1 % of the screened HIV 
peptide pools implying that this overlap between compartments is not absolute (Ibarrondo 
et al., 2005). There have also been contradictory reports of differing HIV epitope-
specificities between cervical and blood-derived CTL (Shacklett et al., 2000). The need for 
a greater understanding of cervical T cell responses to HIV is evident. 
1.1.8. Summary 
In conclusion, there is compelling evidence to suggest that distinct HIV variants occur in 
the mucosa compared to the periphery, which may result in differences in HIV -specific T 
cell responses. There is, however, conflicting evidence to support this. While most studies 
have focused exclusively on comparing HIV specificity between compartments, no studies 
have described the differentiation status of T cells at these two anatomical sites. 
Accumulating evidence for HIV -specific CTL responses at the mucosa stresses the 
importance of understanding local immune responses to HIV to aid the design of efficient 
treatments and mucosal vaccines to prevent the transmission of HIV at mucosal surfaces. 
Since most infections are acquired through heterosexual transmission, with the risk of 
women becoming infected being 2-fold higher than men (Mertens and Burton, 1996), there 
is an urgency to develop effective preventative measures for those currently most at risk. 
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1.1.9. Project aim 
The aim of this project was therefore to compare the HIV-specific T cell function and 
phenotype in the genital tract and in peripheral blood. I focused on expanding HIV -specific 
cervical T lymphocyte populations by either polyclonal expansion or T cell cloning by 
limiting dilution. The functional characteristics of HIV -specific T cell clones at the cervix 
of HIV -infected women were compared with that of T cell clones generated from their 
peripheral blood in order to determine whether compartmentalisation of the HIV -specific 
immune response occurs between the periphery and female genital tract. In addition, the 
maturational status of HIV -specific ex vivo T cells and T cell clones were compared across 
compartments. 
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1.2. Project strategy 
HIV-specific T-cell responses at the site of heterosexual transmission in women, the genital 
mucosa and cervix, is poorly understood. The low yield of T cells generally obtained from 
the genital tract by popular non-invasive methods (Coombs et al., 2003) hampers in-depth 
functional analysis of HI V-specific T cells in the genital tract. 
Various techniques are available to study antigen-specific responses in circulating T cell 
populations. ELISpot, intracellular cytokine staining, and MHC-tetramer staining and flow 
cytometry allow for detection of responses in populations with extremely low frequencies 
and are therefore commonly used in studies of cellular immunity (Ogg and McMichael, 
1999). The IFN-y ELISpot assay is widely used to measure the frequency of T cells capable 
of antigen-specific cytokine secretion (Lalvani et al., 1997). It does not, however, have the 
advantage that both intracellular cytokine staining and MHC-tetramer staining have in the 
ability to simultaneously phenotype those antigen-specific T cells (Gillespie et al., 1999). 
MHC-tetramer staining has a further advantage in differentiating between T cells with high 
and low affinity for specific epitopes as this allows efficient purification of the most 
effective T cells for study or treatment purposes (Dunbar et al., 1995). This study has 
focused on the use of IFN-y ELISpot and intracellular cytokine staining and flow cytometry 
to assess both the magnitude and specificity of T cell responses at the cervix and in blood 
to HIV Gag in women with chronic HIV infection. 
Cytobrush-mediated sampling of the cervix is a relatively non-invasive technique that 
yields adequate numbers of T cells for limited analysis of functional HIV -specific activity 
of CDS+ T lymphocytes (Musey et al., 1997; Shacklett et al., 2000b; Kaul et al., 2000, 
2003; Prakash et al., 2004). For more in-depth studies of cytolytic function, epitope 
specificities, and T cell receptor clonotypes of T cells isolated from cervical cytobrush 
specimens, in vitro expansion techniques are increasingly being employed (Musey et al., 
1997, 2003; Ibarrondo et al., 2005). Polyclonal in vitro expansion of antigen-specific 
memory T cells has often been applied in studies in blood (Jones et ai., 2002), and has 
achieved the same success in mucosal studies by allowing the study of T cell subsets that 
would not, by virtue of their initial frequency in vivo and low sampling-associated cell 
recovery, easily be observed directly ex vivo (Musey et al., 1997, 2003; Shacklet et al., 
2003). Similarly, T cell cloning by limiting dilution allows the further study of virus-
specific cellular interactions at a single cell level (Musey et al., 1997, 2003; Appay et al., 
2000) and shows great promise in allowing a greater understanding of HIV -specific T cell 
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homing patterns, ontogeny, and specific function in samples with low frequencies of a cell 
subset of interest. The present study has compared various strategies to assess HIV Gag-
specific responses. These included ex vivo assessment as well as in vitro polyclonal 
expansion of cervical mononuclear T cells. Because of the severe sample size restrictions 
of ex vivo (which are only partially overcome by short-term in vitro expansion), this study 
has largely focused on T cell cloning by limiting dilution as a mechanism to precisely 
evaluate single-cell phenotype and function during HIV responses at the cervix. 
To detect CTL activity in low frequencies of antigen-specific CTL the sample is often 
clonally expanded in vitro by co-culturing with inactivated (irradiated) antigen presenting 
cells. Due to the low yield of recoverable T cells from cervical specimens, this method is 
currently essential in the study of HIV -specific CTL at the female genital tract. However, 
this process requires prolonged in vitro stimulation which is likely to distort the frequency 
(and potentially the phenotype) of effector CTL, and therefore provides inadequate 
approximation of the in vivo conditions under which virus-specific lysis may occur. The 
polyclonal expansion of CTL is a qualitative technique useful mostly for the detection of 
HIV -specific CTL. It becomes more quantitative when combined with limiting dilution 
analysis (LDA; serial dilutions of the cell sample to set up bulk CTL cultures; Koup et a/., 
1991; Carmichael et a/., 1993). LDA involves serial dilutions of the cell sample to set up 
bulk CTL cultures. Based on the lowest dilution from which CTL could be detected after in 
vitro stimulation, mathematical techniques (Poisson distribution) are applied to determine 
the CTL effector frequency in the primary sample. However, LDA has often been argued to 
underestimate the actual effector cell frequency (Gotch et a/., 1990) and to correlate poorly 
with effector frequencies estimated using HLA-peptide tetramer technology or ELISpot 
analyses (Tan et a/., 1999). This is probably due to LDA measuring only those virus-
specific cell subsets that are able to proliferate under limiting dilution conditions, thereby 
missing those CTL which, have poor proliferative capacity e.g. either effector T cells, 
terminally differentiated, apoptotic in tissue culture (Lewis et a/., 1994; Lloyd et a/., 1997; 
Monteiro et a/., 1996). This poses a problem in studies of immune responses in chronic 
HIV -infection. However, polyclonal expansion is particularly useful in its sensitivity as it is 
able to detect antigen-specific responses to a frequency of 1I1xl05 cells (Goh et a/., 1999). 
Characterisation of strong memory CTL responses to antigen at the clonal level is common 
in studies in blood (Weekes et a/., 1998, 1999; Wills et a/., 1999). Due to the low yield ofT 
cells generally obtained from the genital tract, the merits of clonal expansion of T cells 
from the cervix are increasingly being recognised (Musey et a/., 1997, 2003). After 
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polyclonal expansion of CTL, HIV -specific CTL can be cloned by limiting dilution to 
allow further studies of HI V-specific CTL responses at an individual cell level. These more 
in-depth studies often involve the analysis of T cell receptor usage by the CTL. 
Because compartmentalization of function and specificity of HIV -specific T cell responses 
between the genital tract and blood remains unresolved, the aim of this project was to (i) 
generate and characterize T cell clones from the cervix and blood of chronically mv-
infected women and (ii) determine if compartmentalization in phenotype and specificity 
was evident in this cohort. This study focused exclusively on the Gag region of HIV 
because (i) previous studies have shown that the majority of individuals respond to epitopes 
in this region of HIV in blood and cervical compartments (Musey et al., 2003); and (ii) low 
cell yields preclude extensive genome mapping so the most conserved region of HIV was 
selected. 
The first objective of the study was to screen 35 chronically HN -I infected women for 
responses to HIV-I Gag in peripheral blood by IFN-y ELISpot to identify women with high 
frequencies of HN -specific T cells in blood. The second objective was to investigate HIV-
specificity in cervical mononuclear cells after polyclonal in vitro expansion with anti-CD3 
and to the largely conserved HIV -I Gag to determine whether mv -specific T cell 
responses could be detected after culture in mucosal specimens. Finally, the third objective 
of this study was to generate matched cervical and blood-derived T cell clones by limiting 
dilution to compare both the phenotype and specificity of HIV -specific T cell responses 
between the blood and the genital mucosa at the clonal level. 
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In 2004, infections with HIV -1 subtype C accounted for 50% of all HIV infections 
worldwide and is currently the predominant clade affecting Sub-Saharan Africa (Hemelaar 
et al., 2006; van Harmelen et al., 1999; Novitsky et al., 2002). The HIV subtype C 
epidemics are commonly defined by high prevalence rates in the adult population 
(Hemelaar et al., 2006), high likelihoods of vertical transmission (Renjifo et al., 2001), 
high viral loads (Neilson et al., 1999), being preferentially R5-tropic (Abebe et al., 1999), 
containing several unique subtype signatures across the viral genome (Novitsky et al., 
1999) and by displaying great viral diversity (van Harmelen et al., 2001). As a result, 
numerous studies have focused on the comprehensive analysis of HIV -1 subtype C-specific 
immune responses in blood of HI V-infected individuals (Novitsky et al., 1999,2002-2003; 
Masemola et al., 2004; Kiepiela et al., 2007). 
Several studies have demonstrated the importance of virus-specific CD8+ T cell responses 
in controlling SN and HIV infection (Jin et al., 1999; Klein et al., 1995; Walker et al., 
1986). Strong cytotoxic T lymphocyte (CTL) responses are associated with a decline of 
plasma viremia in acute HIV infection (Borrow et al., 1994; Koup et al., 1994) and with 
viral control (Ogg et al., 1999). Similarly in SIV models of infection, the presence of CD8+ 
T cells was associated with control (Jin et al., 1999; Schmitz et al., 1999). However, CTLs 
fail to prevent infection, and efficient CTL responses are continually challenged by viral 
escape from immune recognition (Borrow et al., 1997; Goulder et al., 1997, Price et al., 
1997) as well as increasing viral genetic diversity (Coffm, 1995; Ho, 1996; Philpott et al., 
2005; Robertson et al., 1995). 
Numerous studies have provided conflicting data on the association between HIV viral load 
and the CD8+ T cell response. While some studies have demonstrated no correlation 
between overall HN-1-specific IFN-y production by CD8+ T cells and plasma viremia or 
CD4+ T cell counts (Addo et al., 2003; Edwards et al., 2002), others confirm that CD8+ T 
cell responses directed against HIV Gag have the ability to reduce viral set-point and are 
therefore important in controlling HIV infection (patke et al., 2002; Geldmacher et al., 
2007). Several studies have demonstrated inverse correlations between viral load and the 
magnitude and breadth of the HIV Gag p24-specific CTL response (Kiepiela et al., 2007; 
Masemola et al., 2004; Novitsky et al., 2003; Edwards et al., 2002). Furthermore, targeting 
of certain HN Gag epitopes, particularly within the highly conserved p24 region, can drive 
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strong selection pressure on the virus, evidenced by lower viremia (Kiepiela et al., 2007; 
Martinez-Picado et al., 2006). 
Various sensitive immunological methods have recently been developed to allow more 
comprehensive assessment of HIV -specific cellular immune responses, including ELI Spot 
and flow cytometry. For more in-depth investigation of the breadth and magnitude ofT cell 
responses to HIV, many studies have utilised arrays of overlapping peptides based on clade 
consensus sequences of HIV or sequences modelled on laboratory isolates. However, it is 
now clear that use of peptides based on consensus or laboratory isolate sequences 
underestimates the frequency of responses directed against variable regions of these viral 
sequences compared to autologous virus (Draenert et al., 2002; Altfeld et al., 2003). The 
use of consensus sequence peptides resulted in failure to detect 28% of peptide-specific T 
cell responses recognised by autologous virus sequences (Altfeld et al., 2003). 
Furthennore, 66% of these missed responses were located in the more variable regions of 
the virus (Vpr and Tat; Altfeld et al., 2003). It is therefore likely that the observed poor 
correlation between HIV -I-specific T cell responses and viral load or CD4+ T cell count 
(Addo et al., 2003; Edwards et al., 2002) may be confounded by the use of reference 
strains of HIV instead of autologous virus. It is important to note, however, that the strong 
correlation reported by Kiepiela et al. (2007) between the magnitude of Gag-specific 
immunity and lower viral set-point was only significant in a cohort exceeding 400 
participants indicating the importance of large cohorts to accurately define these correlates 
of protection. 
The primary aim of this Chapter was to defme both the magnitude and breadth of HIV 
Gag-specific in peripheral blood of chronically HIV -infected women. Numerous studies 
have focused on the comprehensive analysis of HIV -1 subtype C-specific immune 
responses in the blood ofHIV-infected individuals as HIV-l subtype C infections account 
for the largest proportion of HIV infections worldwide (Hemelaar et al., 2006; van 
Harmelen et al., 1999; Novitsky et al., 2002). More relevant to this study, HIV-l subtype C 
is also currently the predominant clade affecting Sub-Saharan Africa (Novitsky et al., 1999, 
2002-2003; Masemola et al., 2004; Kiepiela et al., 2007).This study has focused on Gag as 
this has previously been shown to be one of the most immunodominant regions of HIV 
with preferential targeting by both peripheral blood T cells (Addo et al., 2003; Ramduth et 
al., 2005; Masemola et ai, 2004; Novitsky et al., 2002; Kiepiela et al., 2007) as well as 
mononuclear cells associated with the genital mucosa (Musey et al., 2003). In addition to 
providing insight into the frequency and targeting of peripheral blood T cell responses to 
HIV Gag in this cohort, results presented in this chapter will be central to selection of 
26 
appropriate donors for inclusion into mucosal studies (Chapter 3). mY-infected women 
with the highest magnitude of H1V -1 Gag-specific T cell responses in blood will be used in 
subsequent studies of associated H1V -specific immunity at the cervix. 
27 
Chapter 2 
Characterisation of peripheral blood HIV-specific 
responses to HIV Gag by IFN-y ELISpot in chronically 
HIV-infected women 
2.2. 
Materials and Methods 
Page 
2.2.1 Study population 29 
2.2.2 Blood collection and processing of PBMC 29 
2.2.3 Quantification of lymphocytes in suspension by 30 
Trypan Blue staining 
2.2.4 Cryopreservation of PBMC 31 
2.2.5 Thawing of cryopreserved cells 32 
2.2.6 Preparation of the HIV-1 subtype C Du422 32 
overlapping peptide pools 
2.2.7 IFN-y ELISpot to detect HIV Gag-specifiC T cell 34 
responses 
2.2.8 Statistical analysis 37 
28 
2.2.1. Study population 
Thirty-five chronically HIV-infected women with CD4 counts >300 cellslul were enrolled 
in a longitudinal study of the impact of HIV infection on abnonnal cervical cytology (in 
collaboration with Prof Lynette Denny, Dept Obstetrics and Gynaecology, University of 
Cape Town). In the study, each woman was followed-up 6 monthly at which blood CD4+ 
T cell counts were monitored using BD Trucount CD3/CD4/CD8 reagents and F ACS 
Caliber flow cytometry. Plasma HIV-l RNA levels were determined at enrolment into the 
study and at eighteen months after their first visit using the Amplicor Monitor® system, 
according to the manufacturer's instructions .. The study has been approved by the 
University of Cape Town Human Research Ethics Committee (DCT REC ref: 106/2002). 
Only women who gave informed consent were entered into the study. 
2.2.2. Blood collection and processing of PBMC 
At each scheduled study visit, 40 ml Acetate Citrate Dextran (ACD) anti-coagulated whole 
blood was collected into BD vacutainer tubes by venipuncture. Peripheral blood 
mononuclear cells (PBMC) were isolated from whole blood by Ficoll-Hypaque density 
gradient centrifugation within 3 - 6 hours of venipuncture using Leucosep® tubes (Greiner 
Bio-one). This method separates by density the lymphocytes from red blood cells, 
granulocytes. erythrocytes, and platelets. Lymphocytes and platelets have a lower density 
than red blood cells and granulocytes and are therefore collected on top of the Ficoll-
Hypaque layer (Figure 2.2.1) while red blood cells and granulocytes migrate through the 
Ficoll cushion to pellet at the bottom. The lymphocytes are further purified from platelets 
by subsequent washing steps (Kanof et al., 1994). 
To prepare the Leucosep® tubes for PBMC isolation, a 15ml volume of Histopaque 
(Sigma®) was poured onto the porous inert barrier of each Leucosep® tube and the tubes 
were then centrifuged for I minute at IOOOxG (2300rpm using a Heraeus I.OR Megafuge) 
at room temperature to force the Histopaque through the porous barrier. The presence of a 
barrier served to stabilize the gradient interface and to prevent the PBMC contacting both 
the separation medium and erythrocytes after centrifugation. A volume of 40ml of fresh 
HIV-infected blood was split equally into 2 Leucosep® tubes containing Ficoll and the 
gradients were then centrifuged for 15 minutes at IOOOxG (2300rpm using a Heraeus I.OR 






Figurr 2.2. 1. h olat ion of I'IJM C by f'ifOU· II) p"qllf gnllJifnt ~("n trifllgalion . Whole 
blood was polin."!! OnlO :I poroliS barri<-r abo~e a I:I}<.'T o f !lCpamtion media in II LClIcoS<'p,x 
lube and th~~l cenlrifUt;~"!! (shown In kft diIlI;TlIm). l)uring ct:nlrifugmion. peripheral blood 
mononuclcar Cl'IIS are scpMlIIed from Ihe resl o f the compoTlC."niS of blood by \ inuc o flheir 
dcnsilY (shown in righl diugrtun; a,ja~<"!! from Kanof 1'1 /J/ . 1m). 
The burr) 1/t)CT enriched for lymphoc)tl'S (Figure 2.2.11 was careful!) re moved ""ilh a 
rlastie srnduatcd Pasteur pip"ue (C.)pan InnO\'alion) and traru.f<'fTOO 10 II dl.".m SOml tube 
tCellSlarl.). The I'BMC buffy l3)er WIIS then washed t"ice in a \()Iwnc of 35m I R I (1% 
t'ocl.:Il Cal f Serum (FCS) (lklta Bioproducts) in RPM I 1640 contalnmg SOU penicillin. 
SOmglml streptomycin, 50mglml glutamine (Gilx:oH ' ) and 0.8mglml h ngin lM 
(In\·imG.:nJ\ al J20xG (1300rpm using a Hcmcus 1.0R Mc-gafugr) for 10 minutes 3t room 
temprofllluTC. Fina ll y the cell pellet was resuspended in Sml RI and II \()Iumc of SO,II WIIS 
r"mo\....:I for citht"f aUhlfll,1tl'(l cd I eountmg using a Coultt"f ~'OUIll tr (1k'I:1.m:m Couht"r MDI 
18) or for manual c(llmling. The cell counlS "ere done in duplicatt and Ihe mean of the 1"0 
readings ,,-as caleuiat<'(l 
2.2.3. Q uantiliclHion ofl YlIlphocytcs in suspcnsion by T r.Yllun 
Billc sillin ing 
A o.~% dilutIOn o f Trypan Blue smin (Sigm,1iJ') "'as llsed to distinguish living from dead 
cells based on cell membrane permealJility. Since dead or d}'ing cells lose the intqp1t), of 
tlJei r cdl membmllC'S, Tl)pan Blue (Sigma~) can enter these more pcnneable cdls making 
dend cells appear blue under a light microscope. Manllal cell counts "ere pcr{ollll<d using 
f ast-Read counting chambers (BioSigma). These ckar plastic disposable slides con~iSI of 
10 sepamle counting chambc'rs each with a chamber \'olulllC ofO. lmm' (H gure 2.2.2), 
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F~hly isolated or thll"ed cryo-preserved PBMD were diluted 1:1 with Trypan Blue 
(SigmaiJ). Stainl'd cells were placed in II plastic counLing chamber for counTing by Tr)"pan 





, • ~- • • , ~ , , -
.:..1 --~ 
Figu re 2.2_2. T he F'lIsl- l{elid ~oun t i ng chamb~r slide. (A) Loading of the Trypnn Blue-
cdl suspension into the counting chambers (0) Each clear plastic slide consists of lOx 
0.1 mm' l"Oul"lting chambers eacll containing 16 ~ 1 mml squares. Two large squares (X. Y) 
were counted. 
The counting eh~mber is made up of 10 counting chambo..-rs each containing 16 ~ I mOll 
squal'.'s. Using a s\Jll1dard ligh t microscope. cells an: counted in the lOp !eft square (Figure 
2.2.2.B block Xl and diago na!ly opposite bonom right squaI'C (Figure 2.2.2.0 block V). 
The final cd l concentration was determined using the following equation: 
Blocks X + Y 
Number of eel ls/m! ~ Number of squares counl~d 
(i.e. 2) 
2.2.4. Cryoprescrvalion of rOMe 
x Dilution factor x 
(i .e. 2) 
10' 
To cr)"oprcscn'l: the PBMe for long-tcrm storage. cells .... -ere adjUSted to l xl07 cells per ] 
011 freeljng medium [10% Dimethyl Sulphoxide (DMSO) (Sigma'iJ) in FCS (Delta 
BioproducTS)J. One ml of cells in fn:c7jng mediwll was then transferred 10 each clearly 
labelled eryoviaJ (Gre iner Bio-one) which were then immediate ly tmnsfern:d inlo pre-
cooled (4 'C for Ihr) Mr Frosty@ (Nalgene) containe-fS to facilitate ave-might freezi ng al 
l"e/min III -8O"C. Ce-II~ Stored at -80"C o"emighT were trnnsferred to liquid nitrogen tbc: 
folio" illg day f", 101111. te,,,' ~lOragc. 
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2.2 .5. Thawing of cryoprescrvcd cells 
CI')'o-prescrved PBMCs were retrieved frolll liquid nitrogen and were placed in a water 
bath al J7"C umil almOlst completely thawed. The cells were quickly resuspended in Iml 
warmed RI 11% FCS (Delta lliOlProrlucts) in RP1'oU 1640 containing SOU penicillin. 
SOmglml streptomycin. 50mglml glutamine (GibcOl™) and O.8mg/ml Fungin™ 
(Inv;voGcn)). The solu tiOln was then made up \() 10mi in a SOm! lube (CeIiSlar®) with RI 
added drop .... ise. The tube was tilled with 25ml RI ~nd cent rifuged III nOxG (IJOOrpm 
using a Hemew;: I.OR Megafuge) for 10 minutes. The supernatant was discarded and the 
pelic-\Il'suspcndcd in 500ul 0.002% DNase (Roche) in RPMI 1640 (GibcOl™) for 2 minutes 
10 prevent dumping of cc::lls. The lube was again filled with 2Sml R I and the washing step 
was repeated. The supernatant was discarded and the pellet was resuspended in 2ml R10 
r20% FCS (Dc:lta IliOlproducts) in RPMI 1640 comaining SOU penicillin. SOmg/ml 
slreptOlm)·cin. SOmgiml glutamine (GibcolM) and O.8mgiml Fungin1M (In\"ivoGen»). 
2_2.6. Preparation of the HIV-1 subtype C 1)11422 Gag 
ovcrllll)ping peptide pools 
Lyopholise:d overlapping Gag peplides derive\! from lilY_I ImIHype C Du:J22 ~uence 
were kindly provided by Dr Clive Gray (NICD, Joh."lnl.!soorg. South Africa). Sixty six IS· 
2!J..amino acid long Gag p'-'plides (overlapping by 10 amino acid..~) spanning lhe elllire my-
I subtype C DlI422 Gag protein were used in this study. These: 66 individual IYOlpholiscd 
Gag peptides were diluted in SO~d DMSO (Sigma"') to provide a final peptide 
COlneentmtiOlIi of 20mglml and Ihese were stored in 5 III aliquots as stock solutions al _80°C. 
From these stocks, individual P'!ptides were combined into 5 pools. Pools 1 to 4 comprised 
1-1 pcptides each while Pool 5 eOlntained only 10 pcptides. The final COlncentmtiOln of each 
peptide in II pool (worting stocks) WII$ SOJ-lgim1. Pool I and the beginning Olf Pool 2 span 
HIY-l Gag matrix protein p17; the end of pool 2. the whole pool J, and beginning of pool 
4 span the highly conserved I IlY-1 Gag capsid protein p24: wh ile the end Olfpool 4 and the 
whole o f pool S span HIV-I Gag nucleocapsid protein pIS. 'll1e urmngement or Ihe~ 
Olverlapping Gag peplidcs and pools is c!eltIly ill uslmk-d in Figure 2.2.3. 
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2.2.7. IFN-y ELISpot to detect HIV Gag-specific T cell 
responses 
Cryo-preserved PBMC isolated from HIV -infected women were thawed and incubated 
overnight at 37°C before assessing IFN-y production. mv Gag peptide pool-specific 
IFN-y secretion was assessed by IFN-y ELISpot to characterize the frequencies of HIV 
Gag-specific T cells in the blood of these chronically infected women. Donors with the 
highest frequencies of blood HIV responsive cells were included in HIV -specific 
mucosal studies (Chapter 3). 
Nitrocellulose-backed 96-well plates (Millipore) were coated with 50J.Lllwell IFN-y 
capturing monoclonal antibody I-DIK (5J,lg/ml; Mabtech) in PBS (Gibco™). The 
plates were sealed with self-adhesive plastic sealers (Fasson®) and kept at 4°C 
overnight to allow binding of the antibody to the nitrocellulose membrane. The plates 
were washed three times with 200J,lllwell sterile PBS (Gibco™) to remove excess 
coating antibody. A volume of 100J,l1 RIO [10% FCS (Delta Bioproducts) in RPMI 
1640 containing 50U penicillin, 50mg/ml streptomycin, 50mg/ml glutamine (Gibco TM) 
and O.Smg/ml Fungin™ (InvivoGen)] was added per well and the plates were kept in 
the dark at room temperature for 2 hours to allow for the saturation of the remaining 
binding sites with RIO (blocking). 
A representative template of an ELI Spot plate is illustrated in Figure 2.2.4. Each plate 
included triplicate wells containing PBMC and HIV Gag peptide pools, in addition to 
the mitogen phytohaemagglutinin as a positive control (PHA; FLUKA), and 0.14% 
DMSO (Sigma®) in RPMI as the negative control. The quantity of DMSO included in 
the negative control wells matched the final concentration of DMSO present in the Gag 
peptide cultures. For detection of HIV Gag pool-specific responses, a volume of 50J.tl 
PBMC (2xl06/ml) containing lxIOs cells were plated per well with a volume of 50J,l1 of 
each of the respective HIV -1 subtype C Gag peptide pools 1 - 5 (fmal concentration 
2J,lg/ml). For detection of background IFN-y production, negative control wells 
contained a volume of50ul ofPBMC (2xl06/ml) with 50ul 0.14% DMSO (Sigma®) in 
RIO. As a positive control, a volume of 50ul of the mitogen PHA (FLUKA) in RIO 
(final concentration O.OOSmg/ml) was added to 50ul PBMC (2xl06/ml) per well. 
To monitor inter-plate and assay variability, each plate also included quality control 
wells containing PBMC from a HIV negative donor with well characterized response 
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frequencies to CEF peptides [Cytomegalovirus (CMV), .Epstein Barr Virus (EBV) and 
influenza virus (Elu) immunodominant peptides]. Each ELISpot plate developed in this 
study had to fall within 9% CV of the mean CEF response determined for this quality 
control donor. To do this, each plate included wells with PBMC (2xI06/ml) from this 
HIV -seronegative donor (with known ELISpot-derived IFN-y-specific responses to 
CEF peptides) stimulated with either CEF peptides (fmal concentration If.1g1ml), 0.14% 
DMSO (Sigma®) in RIO, or PHA (FLUKA) (final concentration 0.008mglml). CEF 
peptides are derived from three common human viral pathogens. The immunodominant 
epitopes making up the pool are restricted by 11 common HLA class I molecules 
(Currier et al., 2002). It is therefore likely that a large proportion of the population 
would generate memory responses to this peptide pool. Lyopholised CEF peptides were 
kindly donated by Dr Clive Gray (NICD). The peptides were reconstituted to 5uglml in 
100ul DMSO (Sigma®) to produce a stock, and were diluted further 1:125 in DMSO 
(Sigma®) for a working stock of 40uglml. The CEF peptides were used at a final 
concentration of 1 uglml in the ELISpot assays. 
To identify a suitable CEF-responsive quality control donor for this study, PBMCs 
were isolated from ten buffy packs obtained from the Western Province Blood 
Transfusion Service (Pine lands, Cape Town, South Africa) and were screened for 
responses to CEF peptides by the IFN-y ELISpot assay. Each donor's PBMC was 
plated at I xl 05 cells/well with CEF peptide (final concentration I uglml) in replicates of 
20 to determine the standard CEF response frequency. The donor with the highest mean 
CEF response frequency (out of the 10 donors investigated) was selected for the quality 
control experiments. To ensure that inter plate variations were not contributing to the 
observed difference in magnitude measured in the 35 donors, each of the IFN-y 
ELISpot plates developed to determine HIV -specific responses in the 35 donors also 
included quality control wells with PBMC from a donor with a well-characterised CEF-
specific IFN-y response and CEF peptides. For a plate to be considered for inclusion in 
the study, the CEF response frequency on the QC sample had to be 2157 SFU/l06 
PBMC ± 9% CV (range 1963.6 - 2350.4 SFU/I06 PBMC). 
Following addition of HIV Gag peptides, cells, positive and negative control reagents 
to respective wells, the plates were incubated at 37°C with 5% C02 for 24 hours to 
allow for cytokine secretion. 
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Figure 2.2.4. Representative layout of the IFN-y ELISpot plates used to investigate 
HIV Gag peptide-specific T cell response frequencies in chronically HIV -infected 
women. Each plate included PBMC isolated from 4 donors plated at lxl05/well in 
triplicate wells containing HIV Gag peptides pools (final concentration 2uglml), wells 
containing 0.14% DMSO in RIO (negative control), and O.OOSmglml PHA (positive 
control). Quality control wells contained PBMC from a HIV negative but CEF positive 
individual and 0.14% DMSO in RIO, CEF peptides (final concentration luglml) and 
O.OOSmglml PHA were included on each plate. Three wells containing media alone 
were included to determine background IFN-y production in the media. 
After 24 hours of incubation in the presence of peptide antigens and PHA, incubation 
was halted and cells removed by six washes with 200jJllwell PBS-Tween [10mM PBS 
pH 7.4; 0.05% Tween 20 (Sigma ®) dissolved in 11 RO water] using an ELx50 Auto 
Strip Washer (Bio-Tek Instruments, Inc.). Biotinylated IFN-y-detection monoclonal 
antibody 7-B6-1 (luglml; Mabtech) in 10% FCS (Delta Bioproducts) in PBS (Gibco™) 
was added to the plates at a volume of 50j.1Vwell. The plates were then kept at room 
temperature in the dark for 2 hours. The plates were washed six times with PBS-Tween 
using an ELx50 Auto Strip Washer (Bio-Tek Instruments, Inc.) to remove excess 
antibody. A volume of 100j.1Vwell of Streptavidin-HRP (BD Pharmingen™) diluted 
1:500 in 10% FCS (Delta Bioproducts) in PBS (Gibco™) was added and the plates 
were kept at room temperature for 1 hour. 
Finally, the plates were washed six times with PBS-Tween using an ELx50 Auto Strip 
Washer (Bio-Tek Instruments, Inc.) and 100j.1l1well Nova Red™ substrate (Vector®) 
was added. The reaction proceeded for 6 minutes at room temperature in the dark. The 
plates were rinsed with cold tap water to stop the reaction. 
The plates were air-dried in the dark overnight and the resultant spots (spot forming 
units; SFU) were counted with an ImmunoSpot® Series 3B Analyzer (Cellular 
Technology Ltd.) using ImmunoSpot® Version 3 software. Background IFN-y 
production was assessed in wells containing the PBMC in RIO but with no stimulus. 
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This was subtracted from the SFU detected in experimental Gag peptide-containing 
wells and the difference was normalised to SFU/I06 PBMC plated as per the formula: 
A B 
NetSFU = x 
1 number of cells plated 
where A is the average number of spots in the experimental wells, 
and B is the averafle number of soots in the neflative control wells. 
2.2.8. Statistical analysis 
Medians were compared using the nonparametric Mann-Whitney test. Correlations 
between variables were determined using the nonparametric Spearman rank correlation 
test. Associations between variables in different groups were determined by two-factor 
ANOV A test. P-values less than 0.05 were considered significant. Data analysis was 
conducted using Microsoft® Excel Analysis ToolPak and Prism (version 2.0b, 
GraphPad Software, San Diego, CA) statistical software. 
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HIV-specific responses between 6 monthly visits 
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2.3.1. Clinical details of HIV -infected women included in the 
study 
Thirty five chronically HIV -infected treatment naIve women were included in this 
study. Table 2.3.1 describes the clinical characteristics of these 35 women. The cohort 
had a mean CD4+ T cell count of 498.2 ± 199.9 cells/JlI and a mean viral load of 
62366.31 ± 228657.5 copies/mI. Their average age was 30.3 ± 6 years. Seven of the 35 
(20.0%) women had CD4 counts >600 cellI Jll. All of these HIV positive women were 
enrolled in 2002 in a longitudinal study with 6 monthly follow-up. All women had 
been confirmed HIV positive for at least 2 years with a mean time of follow up since 
enrolment being 26 months (± 2 months). No correlation was observed between 
plasma viral load and CD4+ T cell count (Spearman r = -0.1186, p=0.5180) (Figure 
2.3.1 ). 
Table 2.3.1. Clinical description of the 35 chronically mv -infected women 
included in this studI 
Number of CD4+ Amount of HIV-1 Month b 
DonorlD Age- T cells- (Cells/ul) RNA (Co~ies/ml) In Stud~ 
G014 31 387 68 32 
NY038 31 368 3760 30 
NY040 26 414 9500 30 
NY055 35 335 9100 29 
NY062 26 312 NO 25 
NY064 22 371 1100 25 
NY078 39 327 11778 24 
NY079 23 341 14500 24 
NY094 34 383 468 31 
NY099 21 468 25318 24 
NY100 30 545 15800 24 
NY106 33 1053 NO 25 
NY107 31 393 41700 25 
NY110 36 424 5200 24 
NY130 23 322 39811 31 
NY138 27 607 4013 27 
NY139 33 407 27250 24 
NY150 31 572 3500 24 
NY155 33 451 30000 24 
NY157 43 467 88000 25 
NY162 32 461 7100 25 
NY165 25 363 9942 24 
NY167 27 639 29562 24 
NY172 32 411 4000 25 
NY194 29 466 1818 24 
NY199 36 641 NO 24 
NY229 28 698 1800 26 
NY230 26 1206 3400 24 
NY233 45 573 10987 26 
NY237 30 572 3485 25 
NY240 23 339 47762 25 
NY263 32 400 1300000 25 
NY284 37 533 190000 24 
NY299 20 834 28000 24 
NY302 27 354 27000 24 
Mean ± SO 30.3 ±6 498.2 ± 199.9 62366.31 ± 228657.5 26 ± 2.0 
a The ages and CD4 counts of the women were determined at the visit from which PBMC was isolated 
for IFN-y ELiSpot screenings. The tabulated CD4 counts shown correspond with the patients' most 
recent viral load measurement at the time of PBMC isolation for IFN-y ELiSpot screenings. "The time 





Spearman r = -0.1186, p=O.5180 
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Figure 2.3.1 Correlation between plasma viral load and CD4 T cell count in 
chronically mv -infected women. Each data point represents the matched coordinates 
to CD4 count and plasma viral load in each participant. Rand P-values were calculated 
using Spearman Ranks test for correlation. The goodness of fit (F) and P-value is also 
shown for the linear regression model. 
2.3.2. HIV-specific IFN-y responses in HIV-negative 
individuals 
ill order to establish a cut-off for positive responses and to confirm the specificity of 
the IFN-y ELISpot assays, PBMC from ten HIV-seronegative donors (obtained from 
the Western Province Blood Transfusion Service, Pinelands, Cape Town, South Africa) 
were stimulated with HIV Gag peptide pools and assessed by IFN -y ELISpot (Figure 
2.3.2). Assuming no previous exposure to HIV, the level of response to HIV peptides in 
these donors was taken as a reliable measure of background reactivity to these peptide 
pools in this assay. The assay was performed in triplicate and included positive control 
wells containing the mitogen PHA and negative control wells containing no antigen in 
14% DMSO (Sigma®)in RIO (Figure 2.3.2). The average cumulative HIV Gag pool-
specific response observed in the seronegative group was 50.8 ± 2.5 SFU/106 PBMC. 
The cut-off for considering an HIV Gag-response as positive in the HIV -infected cohort 
was therefore determined to be twice the average number of spot-forming units (SFU) 
per HIV Gag pool detected in these HIV seronegative donors or 100 SFU/106 PBMC. 
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Trip licate weUs ~'Qn1aining 
PBfl.IC from a repr~'SI:nlllti\'t· 
IIIV·seronegative donor 
HIV pj pooll ••••• 
IIIV ill> pool 2-·-
IIlV &a& pool )_.-
IIIV PI!: pool 4_ 
IIiV PI pool ~-. 
No onligen 
PIIA 
Figure 2.3.2. Rrprcsrnlalin IF'N.., ELlSI'OT for lin I1I V' st'-ronegali,'c indil'idual 
u s~'d I" ulrulale flll·ufT for pqSilil'C' HIV'sllt't'ifie n·N.., re!lponoa. The figure 
shows a representative EUSpot plat~ of one IIIV-scl'Of\egalive oolWr to the 5 Gag 
peptide ~Is. lhe posith'l: PIIA 00111101 and negative control. The 3venlgC' number of 
SFUIIO I'BMe plated was calculaled per pool and then added 10 iklmnine the 
cumulative response to I llY Gag by the IIIV·seronegative dollOfS. Each spot represents 
nn ind il' iduaI IFN-), SC'Creting cell in each .... ell. Numbers in the left hand romerof each 
weU represent the number of spoIS oounted per well. Spou were counted using an 
3utorlllUOO counter [ l mmunoSpot~ Series J B AnalYln (Cellular Technology Ltd. J 
2,3,3. [\'Illualion of inlel'-aSSlIY lilid inl{,I'-p lal e \':lrililion by 
inclusion of (Iualit~ cQnlrol sa mples rcsponsi\'c to C[F 
pcplides 
Ucrause the IFN-'Y ELISpOl assessments were nol all done on a single plate or a single 
da) , th~ ""as a need 10 monilor inter-plate and experiment variations. To do this. each 
lFN-'Y EUSpol plale devcloped (na IO) included tri plicale quality 00111101 wells wnh 
PB:' IC from an HIV-seroncgat;'·c donor lI ith a "''ell eMmcleriud IFN.., bLlSp" 
response 10 CEF peptides. In itially. JO lilY seronegal ile donors ... ere screened for 
n-sponsc magnitudes 10 CEI' pepcides osiJli 1Ft-.-r ELiSpoI (data 1101 shov.n). llte HlY 
scrunc:gali\'e donor II ith 1111.· highest Il:N -1 response "'liS selected for inclusion in all 
sub;lequml EU Spol experimcnu 3$ the q ual il) conlrol sample_ From 20 repl icates. the 
IIlernge CEF-spa:ific response ma~,'nhude for the HIV seroneguth'e donor selected was 
ck:termim.'d to be 2157 :I: 193.5 SFUfIO$ PBMC. All subs.."quem plates deleloped "ith 
this quality control sample inc luded had to fall \\ithin this prc-dctermined 2157 
SFU/ lO' POMC:i. 9% CV (r\U1ge 1963.6 - 2350.4 SFUlIrf' PBMC). For determination 
of IllV .specific responses in the 35 chronically HIV-infected women. 10 independent 
WN·y ELiSpot pfotes l\t're USi.-d . TIle quali!} control values from all of the 10 plates 
cvahilltl-d 1;:1l "itkin this pre-<ielermined I'llI1ge indicat ing thai the resu lts from 
individuul experiments ,,< .. re comparable "ilk one another (Figure 2.3.3.). The mean 
determined unlong ulllhc quality control SIImples during IFN'l ELISpot screen ing of 
thc 35 HIV·infcetl'(] "omcn was 2312 -1 145.3 S"oUl IO' PBMC (range 1977 - 2347 
SFUl 106 l'IiMC; Figure 2.3.3.). No significant difference in the TMdillll respomc:s was 
obscn·oo bet"cen the experirncnml and ~viousl} -dcterminl-d SUlndard qualiI) oomrol 
plmes (p - 0 .6 129. Mann· Whitoc)· test; I:ib'"llrc 2.3.3.). 
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Figu~ 1.3.3. Variabili l) among Ihe CEF peplide IIUlllil}' touI,",,1 Inlts per phlle. 
Each plate included triplicale we lts of J> BMC and CEF peptide (finnl conccmnuion of 
II'Wml). PBMC and O.l .f% D~·ISO in media. and I'BMC and O.OO8mgfml PHA. (A) 
Reprcst:nlal il'l.' example of Ihe CEF-conlaining. I'IIA-comainin& and m(:d ia-conlllinin& 
wells. (8) No d ifference was obser.·ed in Ihe malian CEF-spccific IFN-l' responses in 
the 20 replicales of the CEF QC donor (blue dots) Wld the 10 prcl'iously-de\(."nninoo 
standard (red dots) qualit~ control plates (p ~ 0.61 29: Mann-Whiuw)' teSl). 
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2.3.4. C harac lcriSlllion of HI V 
IF'N-y rcsl}oll SCS 111 35 
wo men 
Clig pept ide pool-sJ}eci fic 
ehrolli clilly HIV-inrecled 
The frequeocy of HIV Gag·s~i1ic T cdls in blood from eoch of the 35 chronically 
I Jl V·infl~tN "omen included in ihis study W1l5 determined by IFN-r ELlSpot (Figure 
2.3 .4). Only resPOIl5l:S abo\'c II cut-o lT of 100 SFUIlO· PBMC were considered as 
positive. The nel cumulative HIV Gag·specific IFN·"( responses in the cohon ranged 
from undetectable to 10371 Sru/ IO· PBMC (Figure 2.3.4). with 11 mean net cumulative 
response of 3155:1: 2387 SruIIO' PBMC for all 35 II IV·infected women (Figure 
2.3.4). Eight of the 35 women (22%) had responses >5000 SFUll cf PBMC. 20/35 
"omen (SPAll had responses <5000 but > 1000 SFUII06 I' BMC, lind 7fJ5 (200/.) had 
rl"Slxmses <1000 SfUll 06 I"BMC 
The highest magnillJdes of responses in this IIIV·infccLCd cohon were direcled againsl 
IIIV Gag pools 2 (l1'II'an 1268 ± 1575 SFUlIO· PBMC) and 3 (mean 8 13 ± 1159 
SFUfl06 PBMC). and to a lesser extenl towards pools I (mean 473 ± 623 SFUIlO· 
PBt-.K).4 (mean 408 ± 832 SruIlO· PBMC) and 5 (mean 191.42 ± 442 SFllflo' 
PIIMC) (Figure 2.3.5). This confirms thaI the HJV·spedfie responses detected in this 
study "ere dim:ted predominantly towards the p24 region of Gag whieh has previously 
bt-en sho"ll to be one of the more conservN regions of IIi V Gag (Buseyne el al.. 1992: 
Kiepida CI al., 2007). 
Only 4f35 (11 %) of the women responded 10 a ll 5 I-IIV Gag pools (Table.- 2.3.3). The 
majority of women responded 10 only 2 pools {13135. 37%). In lhese wom~n , the 2 Gall 
pool·spc.-ciflc responses were more likely to be directed towards II IV Gog pools 3 (69"/0 
of the women) and 2 (61% of the woml·n). 
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IfN-y IOU""" 10 do,,,,,,,;,,.. ltotir ..... p<>nso: "tagnituJc<; 10 O\'erlapping p<"pIide< 'pannins II IV., SONy!'" C ()u.J12 Gag. Only """,,,Ial"" ,espons<s .1>,,,,. 100 SFlJ Iii PBMC "'ere 
CM,i<kreJ """,ive not IIi V vag p;><>I.;~ir>c fC$pO'lSCS of tn. 10 1I1',I.""""egal;,e 00n01'S are inc luded vn do. grarh to flInhc, emphasis< lhe ,Jrjngency u/ It-.. <'III -off ""I"e [ I 
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lilY Gog POD" "'V Gag ~Ql l H'VGog Po'" J HIY Gog 1'001 ' H.V Gog 1'00 • • 
~
.,'igu re 2.3.S. IJrcadl h lind magnitude or IIIV GMg JIOOI-~p«irH: 11'1'1""1 rfl l,on$e<!I in Ihe 
3S IIIV-infected women. Each d~1Il point n:prt'5offi1S an individual donor's response 10 
each Gag 1'001. with the median response for each Gllg pool represenlCd by 11 billd, hoe. 
The IFN-1 responses have been expressed ru; nel SFtJllo' PIJMC jndicll1ing thai the: 
backgroulld respom;e for each dooor has been subtracted. The solid bars ( ..w fOf p17. hlu. 
[or p24 and gr«n for p iS) under the graph n:present the general Gug regions com:lahng 
\\ilh the individual peptide: pools. A significant difference Wll$ <!b5en"ed bel\\cen !h( 
respective median m V·specific responses directed to the IIIV Gag pools (I' < 0.000 1: 
single faclor ANOVA lest). 
TMbI~ 2.3.2. The hre.dlh and rrequc"c~ of HI " Gag pools recognisro by Ihe J S III V. 
Infc-ctw "-nmen 
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Although mosl o f ~ women n!oognis.ed pool 3 (28135: 80%: Table 2.32), the :J\'Cr:lge 
speci fic IFN-y rc:sj'IOnSl: IlUIWlilu<ie was lo"cr (813 ± 1159 SFU/JOb ['BMe) than ,hal 
directed towards pool 2 (1268 *' 1575 SFUlI06 PBMC; Figure 2.3.5). Fonhcrmore. 
a1thoullh similar numbc:r$ of "omen rcco¥,!iscd pools I IIlId 2 (2lf3S for pool I compared 
\0 24135 for pool 2: Tahle 2.3.2.). the average specific IFN-r response .... 'lIS of higllt:r 
magnitude in pool 2 maro in pool 1 (1268 ± 1575 SFIJI I if I'HMe for pool 2 compared with 
47) ± 623 SFUflO& 1'llMC for pool I), In addition. Hrv Gag pools 4 and 5 arc: IIl()fIl likely 
10 be m:ogn ised in \\omcn recoWlising more pools (Table 2.3.2). .. 
No correlation "'TIS observcd between thc cumul:nivc magnitude of tht" I-II V Gag-specific 
"'sron,es ~",I pl~,on~ vi""'l k",d (SfV!'lnn~n r = _0 ~n()(, r = n I (k)(,) I'Ir ('1)4' r reI! rl'lll"( 
(Spearman r - ·0.2018. p - 0.2H-t9) in this small cohon of chronicall>' mV-infected 
women (Figure 2_3.6). No association was observcd between tlx> number of pools targetcd 
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Figurf 2.3.fi. Relatiuns hip behHen Ihe magnitudc of IIIV Ga~·s Jle ... ifie IFN-r 
respu nscs. Jll asma " iral Load and CI)-t T cell count in ch ronica lly ~II V·inree ttd 
"Ol11 en. IFN-y·spedfic response (measured by ELlSpot) to ovcrlapping p<'ptidcs spanning 
II IV·1 subtype C Gag "'ere compared with pail'\.-d viral loads (A). and CD-t T cell counts 
(8) in thel;C 35 women. baeh squure duta point represents an individual patieni"s respolUlc 
to Gag \ 'CI'SUS 'iral load (Al or CD4 count ( Il). The solid lin" rl'PrcSCl1lS the line:!r 
r¢grcssion curve for each correlation. Sp<'annan rank tc~ t was used to determine the 
siJ:l1ificancc of th" correlation and rand P-"alws for each comparison is shown on the 
graph. 
'J -.. -;,. Selecti on or lIl V-inrected women wifh fhe h ighesf 
rre(llI cneics or HI V Gag-speci fic T cells in blood ror 
T cell clo ni ng ex periments 
To incl'l:asc the probabilit~ of cloning I Il V Gag-spec'ific T cdls by limiting dilution. 9 
dooors "im tlte higiles! ne\ cumulative response: \0 IIIV Gag "ere selected for T cen 
e~ransion experiments. The median HIV-spce ifie IFN-r responJi(' of the 9 selec ted 
illJl"i<.luals w~s 5]99 srUIIO" 1'(J;\lC (ronge 1813-8267 SFUl lO' r BMC) Thi$ "as 
siglllfican(1) greater Ihanlhc median of 19]1 SFUl f06 PB/I.·fC (r.Ifl.l,'C 63 ~ 10]7 s rUllo· 
I'B"IC) ob.cr.·oo in the remaining 2613 5 '"V-infected women Ip<OJlOO8: Mann-WhitrJe} 
t~iiI ; l'igurc 2.3.7). 110" C\ cr. no <.IilTerellCe was ohst'r.·cd bet"i.'en the median ",1111 loods (p 
- 0.19]K) or CD4 T cell counts (p 0.5972) bo..'1"Cffi the nine women selected for T cel! 
cloninll and 111<' renmining 26 IIlV-infecled "omen ( Figure 2.].7). l'he selected 9 women 
had U li1ean CD4 T cell COlli'll of 551.9 .t.. 275.1 edls/ul and a mean ,·ir.ll load of 17895 .t.. 
2lj926 RNA copieS/1ll1 (Tal-Ie 2.3.]), 
'hble 2.3.3. Net rumu l ~ th t III \' ( ;M2·sptdfie n:~fJlJ n ~t~ of til e 9 III V_infec ted " omen 
~clec t ed fo r T cC'U d on ing t\ptrimcn t~ 
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Figure 2.3.7. Comparison of Ihe H I V Gag-specific I "N-r r~sponH', vir!tl load IIntl 
C I)-4 T «II ((lUll'S hc,wccn Ihe 9 ... omen ~ck"'cd for T cdl up'ln~ion tJO pcrimclIls >llltl 
the remaining 26 HI V-lnf« led women in Ihe cohort. Nine women "ilh the greatest nel 
HIV Gag·s~iflC IFN-y responses were se!~I~ for T cell expansion experiments. (A) n.e 
median lIIV Gng-speeilic response obso.·r .... ed in !he 9 women se lected for T cell expansion 
experiments was significantly greal .. r than that observed in lhe remaining WOl1'1e n (p < 
OJ)()()8). (R) No dillercl"ICe was observed belween lhe medians of the viral In:llls (p -
0.1938) or (C) CD4 T cell CQunts (p " 0.5972) belwe.;:n 1~ IWO groups Ml!11n-Whilney U 
lests were applied lQ compilre lhese non-p~l1Imetric variables. Blue d<lts indicate women 
with the highest H[V Gag-specific responses while red dOls indicale !he women 001 
se leCltd for T ce ll expa ll sioJl txperimenlS. 
HIV-spcciiie IFN-r rcspons.:s in thcs.: 9 WOllli:n wcr~ predominantly directed towards Gag 
pools 2. 3 lind 4. the pools spanning the highly conserved b'<!rlC for HIV Gag p24 (F igure 
2.2.3). Re<pn no;es 10 rools 2 nncl 4 we'" signi r'CAntly high~r in Ihes<- 9 ,,'I)ml'n Ihan in lhe 
remaining 26/35 women (Figure 2.3.H.A). Despite the significant difTenmce between Ille 
cumulative m:tJ!.l1illldes of HlV Gag-spcdfic respons<:s between the sclecled group of 9 
wom~n and the remaining women in the cohort (p < 0.0008) (Figure 2.3.7). no significant 
difference " as observed in the breadth of1h~ II IV Gag pool·specific responses between the 
two groups f.p<0.367 8; Figu~ 2.3.SBJ. 
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Fi~ure 2.3.8. CODllllirison of fh e b read ilis lind magniludu of U"N-"!, respon~, direNed 
lowards individual I.IIV Gag [It'p lidl' pools in Ihl' 9 women selecltd for T ce ll 
expans ion uptrimcnt$ ami lbe remaining 26 wumen in tbr cuhurt . The nJa l>llilUdt- (A), 
but not the breadth (8 ) of lhe IIIV-I Gag-specific ",sponSC was significantly dilfe~nt 
bc1ween the twO groups of women. P w illes weJ"C determined by the Mann-Whimcy 
nonparamelric I-lest (A) and two-fac lor ANaYA (0 ). 
so 
2.3.6. Assessment of \'lIria tion of breadth lI ud magnitude of 
HI V-sllec ilic resllO nses between 6 monthly visit s 
rhe IFN·'Y FllSpot assu) wa5 used to Iden tif> IIIV·infected women W11h high frequcTll,:Ies 
of Il IV·specific T cells in blood 10 increase lhe prob:lbili t>· of success In limi l in~ dilution 
stud ll'S "here IIIV·specific T cell5 from thc blood and cc(\ix Ilere subjected to in ritm 
e.~p;lnsion l Chapter J). Sel«tion of hi~ frequellC>' re~fl'Ondcrs and clonin!! of III V -1ipo."C llic 
T cd ls hUH: been performal at 2 COI\St1:UII , e 6 ",(lutl! ,isits for cuch participant. To 
delcnnine whether the obsc:-n 'oo frcqucnc> of li I V-sp~:citic T cells in blood woulJ be 
maintained al the subsequcnt I'isil. li lV Gag-spccitic PBMC responses "eTC dctl"muncd at 
IWO c(m~ulil'c "isi ls in 4 donors (Figun: 2.3.Q), No sif!nifieam diffcrence was obscn oo 
het,,,:c ,, thc mean magnitudi:s of the IIIV-specific responses detected at cach ,isit II' -
0.8410; two-factor A .... OVA: Figure 2.3.9 A). Two of the four donors had SImilar 
mPgTlitudi:s OH'r the 6.mOllth period. Om: of II" fOIiT had a 2.7·fold increase in magnitude 
of Il IV·speciflC n:sponse. and another ltad " 2.6-fold d\Xrcasc in ITliIgnituJe. DespI te 
'urilil ion in the o'crall mlIi:nitudc of responses to the various pools 11\ these donors. the 
breadth of the responses durin!,: the 6'lIlOllths ",us comparable III 3
'
4 donors. Only 1/4 
oonors.l\Yl07. had ~ 5ignific~rt1 difference in I Il V Gag pool-spectfie response II) tWO-
faclOT A:-"'OVA Ip • 0.00(3). This donQr t:xltibitcd pn c~pandro response 10 pool 3. a rIC .... 
response 10 pool I. and II reducro Tl.'spons<: 10 pool 2. AhhQu~ there seems 10 be " 'Irialion 
in magnitude Oler lime. the breadtb of the response at one point cm gi\~ an indication of 
lite rl'Sponse at another time poim. 
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2,3.6. Assess ment of \'ariali on of breadth and mag nitu de of 
m V-sJlec ific reS I)onscs between 6 monthl~' \'isits 
The IN-r ELlSpol asSll~ was used 10 idenlif~ 1I1V-inf~lcd "omen ",iib high frcquencie~ 
of II1V-sp«iI'ic T eells in blood 10 incre:tSC the probabi lil) of sun:e>s in limiling dilution 
siudies "'here HlV.specilk T n'lIs from tile blood and ~eT\i~ "ere slIbjl:'Cicd to in "ilro 
('l(pansion (Ch:aptcr 3). Se!rt lion of high f rl.'qlk'Tl(:} responders and ~Ionin@. oflllV -sp«ific 
T ~eJl~ ha\'e been performed III 2 ~oosecllti\e 6 month \;<i t5 for e.wh participant. To 
deterTllloc whcther the obsencd frequeoc) of IIIV·specifte T cclb in blood would be 
maintained aI the subsequent visit. HIV Gag-spcdfi~ I'BMC response's were det(.'rminoo at 
1"0 eOllSCUlli'e ,isil'> in ..\ donors (Figure 2.3.9). No siJ;f1ificanl dIIT,-/(.'l1<:e was obse{'\loo 
het"ectl the mean magnuu.des of Ih(.' HIV-spedlic responses detecled at (.'u"h I'isit (p -
0.8 ..\1 0: '''o-flKlor ANOVA: Figllre 2.3.9 A). TIIO of the f(lllr dOnlll'S h:,d similar 
rn:lJ;f1imdcs o,'cr ,hI.' 6-monlh period. One of the four had :I 2.7-foJd illCrea.<;t' in m3gni'lldc 
of II I V-~pccific respon5C_ and anolh(.'r had a 2.6-fold dL~rea$f' in nlllgniHldc. Dc-spilc 
Inri,llion in Ihe olcrall mugnitude of responses HI Ih(' lariollS p()ols in these donors. the 
breadth 01' the respon~s during the 6-months "as comparable in JI~ donors. Only I /~ 
donors. NY107. had a .igniiicant ditTen'l1Ct' in IIiV G3g pool-!ipl'cilic responM' h) 1"'0-
fOCIOr ANOVA (P .. O.QO.IJ). This donor exhibi.~-d an expanded responsc 10 pool 3, anI.''' 
response 10 pool l. and a T('ducoo response to pool 2. Although Ibt:re SttIJ1S 10 be lanalion 
in magnilllde (ll(.'f lime, the breadth or Ihe fl"$pon5C 31 one poinl can gill.' an indicauon or 
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In this study, 35 chronically HIV -infected women were assessed for HIV -I subtype C Gag-
specific IFN-y responses by ELI Spot. Only 2/35 women screened did not respond to HIV-I 
subtype C Gag peptides. Concordant with several other reports, CTL responses were 
directed predominantly towards the p24 region ofHIV Gag (Buseyne et al., 1992; Kiepiela 
et al., 2007; Masemola et al., 2004; Altfeld et al., 2003). No association was observed 
between the magnitude of the HIV -I Gag-specific response of these HIV -infected women 
and their plasma viral load or CD4+ T cell count The impact of HIV -specific CTL activity 
on viral load is highly contentious with a number of conflicting reports (Kiepiela et al., 
2007; Masemola et aI., 2004; Novitsky et al., 2003; Addo et al., 2003; Migueles et al., 
2001; Edwards et al., 2002). While earlier studies have shown no association between 
CTL responses and viral load (Addo et a/., 2003; Migueles et al., 2001; Edwards et al., 
2002), others have clearly shown that HIV-specific T cell responses against some regions 
of the genome have significant impact on reducing viremia (Kiepiela et aI., 2007; 
Masemola et al., 2004; Novitsky et al., 2003). T cells targeting Gag in particular have been 
implicated in better disease outcome (Kiepiela et al., 2007). The association between T 
cell responses and reduced viremia was only noted when the cohort exceeded 400 
individuals (Kiepiela et al., 2007) indicating that cohort size may have been a restricting 
factor in the earlier studies. The nature of this association and the factors affecting it 
remains unknown. 
This study has focused exclusively on T cell responses to HIV -I subtype C Gag peptides 
since HIV subtype C is the predominant strain of HIV found in Southern Africa (van 
Harmelen et al., 2003; Novitsky et a/., 2002) and several studies have confirmed that Gag 
is the most common target of HIV -specific responses (Addo et al., 2003; Kiepiela et al., 
2003; Masemola et al., 2004). HIV-infected PBMC were screened for IFN-y responses to 
pools of peptides spanning the entire HIV -1 subtype C Gag protein. Recent comparisons of 
the use of consensus strains versus autologous virus have revealed that use of consensus 
strains underestimates responses directed against variable regions of viral reference 
sequences compared to autologous sequences such that up to 28% of responses will not be 
detected using consensus strains (Draenert et aI., 2003; Altfeld et al., 2003). Furthermore, 
as much as 33% of these missed responses can be located in the conserved p24 Gag region 
(Altfeld et al., 2003). Despite these findings, synthesis of autologous HIV peptides is cost 
prohibitive for studies of even moderate cohort sizes and would not have been relevant or 
feasible for the present study. Since the purpose of this study was to identify a panel of 
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HIV -infected women with high frequencies of HIV Gag-specific T cell responses, the use 
of the peptides based on the HIV subtype C Gag Du422 strain was adequate to determine 
the magnitude of responses. 
In this study, HIV -specific T cell responses were most frequently directed towards the p24 
region (pools 2 and 3) of mv Gag and this is concordant with previous reports (Buseyne et 
al., 1992; Masemola et al., 2002). Furthennore, the women in the cohort were more likely 
to respond to only 2 of the 5 HIV Gag pools, with the targeting of p 15 (pools 4 and 5) 
increasing in frequency with increasing number of pools targeted. In this study, no 
association was observed between number of pools targeted and viral load as previously 
reported (Masemola et al., 2004). 
Of the 35 HIV-infected women screened by IFN-'Y ELISpot, 9 women with the highest 
HIV -specific IFN -y responses in blood were selected for T cell cloning experiments 
(Chapter 3). A significantly higher magnitude of HIV -specific T cell cumulative response 
was observed in this group compared to the remaining 26/35 women in the cohort, with 
most significant increases being observed in the p24 region ofHIV Gag. 
Because I proposed to use magnitude assessment at one visit to predict high responders at 
the next 6 monthly visits, it was of interest to assess the maintenance of frequency of HIV-
specific T cell responses in blood between visits. IFN -y ELISpot screens perfonned on four 
HIV -infected women at two consecutive visits confinned no significant difference between 
the magnitudes of responses between the two time points although clear fluctuations were 
noted. 
The robust and sensitive IFN-'Y ELISpot assays have widely been used for screening large 
numbers of samples for HIV-specific T cell responses and are particularly useful in 
providing information on the immunogenicity of vaccines. However, recent evidence has 
highlighted the importance of polyfunctional CD8+ T cell responses (the simultaneous 
expression of IFN-y, MIP-l-~, lNF-a., IL-2 and degranulation marker CD107a) in 
suppressing HIV replication (Betts et al., 2006). Because it allows assessment of only one 
T cell function, the IFN-y ELISpot assay may not be equipped to determine the functional 
diversity associated with effective immune control. For the purpose of this study, the 
measurement of IFN-'Y-secretion by IFN-y ELISpot was sufficient to meet the aim of 
determining the frequency ofHIV-specific T cells in the blood ofHIV-infected women. 
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In summary, this chapter has shown that T cell IFN-y responses against Gag were common 
in chronically HIV -infected women with 33/35 (94.3 %) women having clear specificity 
against the gag gene product. These responses were focused predominantly against the 
capsid protein p24 which is recognized to be the most conserved. Although this is a 
relatively small study, I found no correlation between T cell IFN-y responses to Gag and 
either CD4 count or viral load. From this analysis, a panel of 9 chronically HIV -infected 
women were identified with high frequencies of HIV -1 subtype C Gag-specific T cells for 




Generation and characterization of 
HIV Gag-specific cervical- and 
blood-derived T cell clones 
57 
Chapter 3 
Generation and characterization of HIV Gag-specific 
cervix- and blood-derived T cell clones 
3.1. Introduction 
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Few studies have thoroughly investigated the comparative function of HI V-specific T-cell 
responses at the genital mucosa with those in blood. One of the primary reasons for this 
being that sampling of T cells from the genital mucosa generally yields too few T cells to 
conduct thorough functional analysis. In-depth studies of cytolytic function, epitope 
specificities, and T cell receptor c1onotypes of T cells isolated from the genital mucosa 
have therefore increasingly employed in vitro expansion techniques (Musey et al., 1997, 
2003; Ibarrondo et al., 2005). Polyc1onal in vitro expansion of antigen-specific memory T 
cells allows the study of T cell subsets that would not, by virtue of their initial frequency in 
vivo and low sampling-associated cell recovery, easily be observed directly ex vivo (Musey 
et al., 1997, 2003; Shacklet et al., 2003). Similarly, T cell cloning by limiting dilution 
allows the further study of virus-specific cellular interactions at a single cell level (Musey 
et al., 1997, 2003; Appay et al., 2000) with potential benefits of better understanding of 
HIV -specific T cell homing patterns, ontogeny, and specific function in samples with low 
frequencies of a cell subset of interest. 
In this study, I investigated the use of T cell cloning by limiting dilution of HIV -specific 
cells from the genital mucosa. Because this process requires in vitro stimulation with 
cognate antigen which is likely to distort the frequency (and potentially the phenotype) of 
effector CTL, it provides only an approximation of the in vivo conditions under which 
virus-specific lysis may occur. The polyclonal expansion of CTL is therefore largely a 
qualitative technique that is useful mostly for the detection of HIV -specific CTL. It can, 
however, become more quantitative when combined with limiting dilution analysis (LDA; 
Koup et al., 1991; Carmichael et al., 1993). Poisson transformation of the cloning 
efficiency can then be applied to determine the CTL effector frequency in the primary 
sample based on the lowest dilution from which CTL could be detected after in vitro 
stimulation (Taswell, 1981, 1984). Because LDA only measures those virus-specific cell 
subsets that are able to proliferate under limiting dilution conditions, it has been shown to 
underestimate the actual effector cell frequency (Gotch et al., 1990). However, polyclonal 
expansion is particularly useful in its sensitivity as it is able to detect antigen-specific 
responses to a frequency of 1 in lxl0s cells (Goh et al., 1999). 
Due to the low yield of T cells generally obtained from the genital tract, the merits of 
clonal expansion ofT cells from the cervix are increasingly being recognised (Musey et al., 
1997, 2003). After polyc1onal expansion of CTL, HIV-specific CTL can be cloned by 
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limiting dilution to allow further studies of HIV -specific CTL responses at an individual 
cell level. These more in-depth studies are beneficial in characterising memory CTL 
responses to antigen at the clonal level (Weekes et oZ., 1998, 1999; Wills et oZ., 1999) and 
in understanding T cell homing patterns and ontogeny (Musey et oZ., 2003). 
Various studies have demonstrated that CD8+ T cells are capable of cytokine secretion and 
cytotoxic lysis but incapable of proliferation in studies of chronic antigenic stimulation 
such as cytomegalovirus and HIV (Wang and Borysiewicx., 1995; Evans et oZ., 1999). On 
first encounter with an antigen, naive T cells are induced to proliferate and kill infected 
cells (Topham et oZ., 1997). Since only certain antigen-specific T cell receptors induce 
proliferation, the T cell population increases in clonality. Subsequent activation-induced 
cell death results in the loss of a large number of activated T cells such that only a small 
pool of memory T cells remain (Ahmed and Gray, 1996; Schmitz et 01., 1999). This 
memory T cell pool will expand more rapidly on re-encounter with the antigen (Ahmed and 
Gray, 1996). Since T cells have a finite proliferative capacity and eventually become 
terminally differentiated and senescent, chronic stimulation by antigen such as is the case 
with HIV infection or cytokine may accelerate replicative senescence (Bestilny et oZ., 2000; 
Palmer et oZ., 1997). Numerous studies have described the expression of CD57 on the cell 
surface of T cells as a marker of proliferative impairment of T cells (Wang and 
Borysiewicx., 1995; Weekes et 01., 1999) and the expression of CD57 has also been 
associated with antigen-induced apoptotic death of CD8+ T cells (Brenchley et oZ., 2003). 
Generally, CD57 expression on T cells is regarded as a marker of terminal T cell 
differentiation. 
In this chapter I investigated HIV -specificity in cervical mononuclear cells after polyclonal 
in vitro expansion and limiting dilution cloning initially with anti-CD3 and then with HIV-
1 Gag to determine whether HIV -specific T cell responses could be detected after culture in 
mucosal specimens. I generated matched cervical and blood-derived T cell clones from the 
women identified in Chapter 2 as having high frequencies of blood Gag-specific T cells. 
These were generated in order to compare HIV -specific T cell responses between the blood 
and the genital mucosa at the clonal level. In addition to determining their HIV -specificity, 
I also compared the differentiation status of the cervical and blood-derived T cell clones 
generated in this study. 
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3.2.1. Isolation of T cells from peripheral blood 
Blood from the women with high frequencies of HIV -specific blood-derived T cells 
(identified in Chapter 2; Section 2.3.5) were collected in Vacutainer tubes containing 
acetate citrate dextran (ACD) (BD Vacutainer). PBMC were isolated by Ficoll-Hypaque 
density gradient centrifugation according to the method described in Chapter 2 (Section 
2.2.2) within 3 6 hours of venipuncture. Between 1 - 2 xl 06 PBMC were analysed ex vivo 
for IFN-y production to HN Gag by intracellular cytokine staining (Section 3.2.5), or were 
used as autologous feeder cells (Section 3.2.7.3.2) during the expansion of T cells. 
Remaining cells were frozen in liquid nitrogen as described in Chapter 2 (Section 2.2.4). 
3.2.2. Isolation of T cells from cytobrush specimens 
Several studies have employed the relatively non-invasive cytobrush-mediated technique of 
sampling for cervical T cells (Musey et ai., 1997; Shacklett et ai., 2000b; Kaul et ai., 2000, 
2003; Prakash et al., 2004; Quayle et ai., 2007). Although well tolerated, this method 
yields few cells for analysis. Cervical lymphocytes were collected according to the method 
described by Passmore et al. (2002; 2006). Briefly, a Digene cervical sampler was inserted 
into the cervical os and rotated 360°, It was withdrawn and transferred to a 15ml V-
bottomed Falcon tube containing 3ml transport medium [10% FCS (Delta Bioproducts) in 
RPMI 1640 containing SOU penicillin, 50mglml streptomycin, 50mglml glutamine 
(Gibco™) and 0.8mglml FunginTM (lnvivoGen)]. Cervical samples were not taken if the 
donor was menstruating, had visible sexually transmitted infection or discharge or was 
pregnant. Cervical samples were discarded if the sample had visible blood contamination. 
Processing was done within 3 6 hours of collection to maximise T cell recovery and to 
maintain viability. 
3.2.3. Processing of cervical T lymphocytes from cervical 
cytobrush specimens 
A plastic disposable Pasteur pipette (Medipack®) was used to flush mucous and cells from 
the cytobrush by pipetting up and down 20 times in 3ml transport medium. The media 
containing dislodged cells was then transferred to a fresh conical-bottomed 15ml centrifuge 
tube and centrifuged at 320xG (1300rpm using a Heraeus l.OR Megafuge) for 10 minutes. 
The supernatant was carefully removed using a disposable Pasteur pipette and stored at -
80°C. The cytobrush was rinsed a second time with another 3ml transport medium and a 
disposable Pasteur pipette was used to dislodge any remaining cells. This second wash with 
3ml transport medium was added to the cells pelleted from the first wash. These cells were 
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gently overlaid onto a 4ml Ficoll-Hypaque gradient in a 10ml round bottom tube and 
centrifuged at 480xG (1600rpm using a Heraeus l.OR Megafuge) for 30 minutes with the 
brake turned off. The buffy layer enriched for mucosal mononuclear cells (MMCs) was 
removed using a disposable Pasteur pipette (Medipack®)and transferred to a fresh ISml 
Falcon tube. The tube was filled with Rl [1% FCS (Delta Bioproducts) in RPMI 1640 
containing SOU penicillin, SOmglml streptomycin, SOmglml glutamine (Gibco™) and 
0.8mglml FunginTM (lnvivoGen)] and was centrifuged at 1300 rpm (320xG) for 10 
minutes. The supernatant was discarded and cells washed a second time with Rl. The 
supernatant was discarded and the cell pellet was resuspended in 400Jl.I 10% human AB 
serum in RPMI 1640 containing SOU penicillin, SOmglml streptomycin, SOmglml 
glutamine (Gibco™) and 0.8mglml FunginTM (lnvivoGen)]. The cell count was determined 
manually using Trypan blue exclusion staining (Section 2.2.3). 
3.2.4. Preparation of the single pool of 66 HIV Gag peptides 
The entire HIV -1 subtype C Gag protein was divided into 66 IS-20-mers that overlap by 10 
amino acids (described in detail in Section 2.2.6). A single pool of 66 HIV Gag peptides 
was prepared for use in this Chapter. The single pool of 66 HIV Gag peptides was used at 
final concentration of 2uglml by diluting the stock of 66 HIV Gag individual peptides 
[concentration of O.3mglml in DMSO (Sigma)] 1 :IS0 in the relevant media for functional 
analysis or T cell expansion. 
3.2.5. Polyclonal in vitro expansion of cervical T cells 
The cervical T cells recovered from cytobrush specimens (Section 3.2.2) were first cultured 
in the presence of anti-CD3 mononclonal antibody for 14 days to expand CD3+ T cell 
populations; and with a single pool of 66 HIV Gag peptides for a further 14 days to expand 
HN-specific CD3+ T cells. Cervical MMC from each donor was aliquoted into 4 wells of 
a 96-well microtitre plate (Nunc) each containing 100 ul. Wells of the 96-well plate were 
pre-coated with 100ul anti-CD3 monoclonal antibody. These wells had been pre-coated by 
adding the 100u1 anti-CD3 monoclonal antibody at a final concentration of lOuglml (R&D 
Biosystems) in PBS (Gibco™) at 37°C or overnight at 4°C and then washing away excess 
anti-CD3 antibody 3 times with PBS (Gibco™) before the addition of cervical MMC. The 
cervical MMC were cultured in the presence of lxl0s/well autologous irradiated (4000 
rads) PBMC (feeder cells). After 14 days, the four wells were pooled and T cells were 
counted manually (Section 2.2.3). The cervical MMCs were re-plated at 1xlOs/well in a 
new 96-well microtitre plate and stimulated with a single pool of 66 mv Gag peptides 
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(section 3.2.4) at a final concentration of 2ug/ml in the presence of fresh autologous 
irradiated PBMC (lx1Os/well) which served as both antigen-presenting cells and feeder 
cells. The cervical MMC were kept at 37°C with 5%C02 throughout the 28-day culture 
period. Recombinant human interleukin-2 (IL-2; final concentration of IOOU/ml; NIH 
AIDS Reagent Repository, Germantown, MD) in fresh media [10% Human AB serum in 
RPMI containing 50U penicillin, 50mg/ml streptomycin, 50mg/ml glutamine (Gibco™) 
and 0.8mg/ml FunginTM (InvivoGen)] was added to each well at the initiation of culture 
and then every second day by replacing IOOul of media in the well. After 14 days of culture 
with anti-CD3 monoclonal antibody and then 14 days of expansion in the presence of HIV 
Gag peptides, cervical T cell lines were then used in T cell cloning experiments or assessed 
for HIV Gag specificity by IFN-y ELI Spot (section 2.2.7). 
3.2.6. Assessment of DIV Gag-specificity of cervical T cell 
lines by IFN-y ELISpot analysis 
Expanded T cells were counted manually after 26-days of culture (section 2.2.3). Cells 
were removed from IL-2 by centrifuging cells at 425xG (l500rpm Heraeus I.OR 
Megafuge) for 5min and resuspending the cells in fresh culture media containing no IL-2 
[10% Human AB serum in RPMI supplemented with 50U penicillin/ml, 50mg 
streptomycin/ml, 50mg glutamine/ml (Gibco™) and 0.8mg/ml Fungin™ (InvivoGen)]. The 
expanded cervical MMC number was adjusted to Ix106cells/mi at 28-days of culture to 
assay for specificity to the five HIV Gag peptide pools. A volume of 50ul expanded 
cervical MMC (lx106/ml; 5x104/well) was added per well on the ELI Spot plate and the net 
IFN-y response to the HIV Gag peptide pools was presented as SFU/l06 T cells. The 
majority of the cervical MMCs were used to generate HIV Gag-specific T cell clones. 
3.2.7. Generation of DIV Gag-specific cervical and 
peripheral T cell clones 
CD3+ T cells from PBMC for T cell cloning experiments were purified using MiniMacs 
(Miltenyi Biotec) magnetic bead purification. The yield of T cells from the cervix was 
insufficient to be purified using this method and were therefore cloned directly after the 28-
day period of polyclonal expansion. 
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3.2.7.1. Magnetic bead isolation of blood-derived T cells for cloning 
3.2.7.1.1. Preparation of microbeads 
The microbeads (MACS) provided by the manufacturer were stored in azide that had to be 
removed before use. A MS Separation Column was placed in to a Minimacs magnet 
(Figure 3.2.1) and rinsed with wash buffer [500ul 0.5% FCS (Delta Bioproducts) and 2mM 
EDTA in PBS (Gibco™)]. A volume of 500ul MACS CD3 MicroBeads (Miltenyi Biotec) 
was passed through the column (attached to the magnet). The column containing the bound 
anti-CD3 microbeads was washed two times with 500ul wash buffer and the eftluent was 
discarded. The column was removed from the magnet and placed into a sterile Eppendorf 
tube. The column bound anti-CD3 microbeads were eluted off the column by adding 500ul 
wash buffer to the top of the column and then plunging the beads off the column using the 
plunger provided to transfer the magnetic beads to an Eppendorf tube. 
3.2.7.1.2. Labelling of PBMC with anti·CD3-coated magnetic 
microbeads 
PBMC (lx107 cells) were resuspended in 80ul wash buffer [0.5% FCS (Delta Bioproducts) 
and 2mM EDTA in PBS (GibcoTM)]. A volume of20ul of the washed anti-CD3 magnetic 
beads was added to 80ul of PBMC. The cells were kept at 4°C for 20 minutes to allow 
specific binding of the antibody to CD3+ T cells. A control sample of 80ul wash buffer and 
donor cells in 20ul 0.5% Foetal Calf Serum and 2mM EDTA in PBS were also placed at 
4°C for 20min to control for non-specific binding of the PBMC to the column (the 
unseparated population). 
3.2.7.1.3. Separation ofCD3+ cells from PBMC 
The MACS MS Separation Column attached to the MACS MultiStand magnet was set up 
as shown in Figure 3.2.1. The column's filter was initially washed with a volume of 500ul 
wash buffer. Labelled cells were pipetted onto the column in the magnetic field. The tube 
in which the labelled cells were incubated was washed with 500ul wash buffer and passed 
over the column to collect residual cells from the tube. The column containing the magnetic 
beads and attached cells was washed three times with 500ul wash buffer. The eftluent was 
collected as the negative fraction. The column was removed from the magnet and placed in 
a clean collection tube. A volume of 1ml wash buffer was added to the column and a 
plastic plunger was applied to the column to flush out the positively labelled cells. FACS 
analysis was used to confirm the purity of CD3+ T cells in this positive fraction. 
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FIgure 3.2.1 . '\ s..~emhly of the MS S('llaration Column lind MACS MulliSl8ml. (t\) The 
MACS muhis1:lnd magnet. the MiniMACS separation unit. the MS Sepamlion column Wld 
plunger are indicated in this figure. ( U) The MiniMACS So!paralion unit is nttnc:hed 10 the 
MACS MuhiSlund m.1gnct. The MS Scpamlion Colunm is then placed in the MiniMACS 
Separation uni!. A colh:.:tioo lube is then placed under the column. A volume of 500u[ 
wa.'<I1 huffer is passed through the column before the immediate addition of the ~11 sample 
(adapted rrom the MACS MS Separation Columns instruction manual. Milten)'; Bj()l~'(:h). 
3.2.7. 2. Limiting dihHion cloning of IH V-SI'('l' iri ... l· ... rvical li nd 
I}('riphl'ral T cells 
Cion ins b)' limiting dilution enlllits plating cells in "ells at a dilution that etl~-ures a high 
probability that lilly re.~u1ting colon)' is derived from a single cdl (Taswel1. 1981). lbe 
lo .... er the uH'r::age number of c;:lb p1:ated per .... ell. the jpl:3ter the probability thaI the 
resultant population is a true clooe. Table ].2.1 summarizes the probability that one ..... ould 
achieve a single cell clone at various plating dilution! ranging fIOfll I cell per "elllO 0.1 
cells per .... ell. If the a,ernge numrer o f cl.'1ls plated per .... el1 is I. then the probability that 
the resultin" cells expanding from that "ell would be cloWlI is only 0.582. In wmraSL if 
the a,·erage number o f cells plated per \\ell ..... us 0.1. then the plObability thaI ao~ ..... ells 
skl ..... ing expansion ure clooal is 0.951. In this stud}. CD]- PBMC and MMC .... ere plated 
al 0.1. 0.3 and 1.0 cdl$lwell into 96-.... ell pluta. 
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Table 3.2.1. Manipulation of the Poisson distribution to determine the probability that 
any cell population picked at random is a true clone 
Average number of cells per well 
1.000 0.300 0.100 
Probability 0.582 0.857 0.951 
Adaptedfrom Davis, 1994 
The frequency of HIV -specific T cells in PBMC of the 9 donors had previously been 
determined (Chapter 2) and this was taken into account when calculating the number of 
HIV -specific CD3+ PBMC that I needed to plate to obtain a frequency of 0.1 HIV -specific 
T cell/well. Table 3.2.2 summarises the number of cells plated per 100ul to obtain a 
frequency of 0.1 HIV-specific blood-derived cells per well. From Table 3.2.1, even though 
the tabulated probabilities are based on the assumption that only single cells are being 
plated and that populations are randomly selected, at an average of 0.1 cells plated per well 
there is still an approximate 5% chance that a population will not be clonal. Therefore, 
further testing by F ACS analysis of phenotype, T cell receptor typing, or further limiting 
dilution (sub-cloning) should be performed to confirm that the selected colonies were 
indeed clonal. 
Table 3.2.2. Plating frequency of blood-derived T cells based on 
previously-determined mv -specific T cell frequency in blood 
Net Cumulative Plating Frequency for 0.1 HIV-specific 
Donor Magnitude blood-derived ceUs/weU 8 
ID (SFU/10B PBMC) (ceUs/100ul) 
NY130 8246.67 12.13 
NY230 6220.00 16.08 
NY055 5746.67 17.40 
NY229 5689.99 17.57 
NY172 5243.33 19.07 
NY094 5236.67 19.10 
NY233 3900.00 25.64 
NY237 3673.33 27.22 
NY157 2466.67 40.54 
-Where frequency was calculated by the equation: Plating Frequency = [106/ magnitude of HIV-specific 
response observed] x 0.1 
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3.2.7.3. Maintenance of HIV -specific T cell clones 
T cell clones were supplied with growth-promoting human recombinant IL-2 and irradiated 
autologous feeder cells (PBMC) to provide the media with the appropriate cytokines, 
chemokines and spatial environment for T cell growth. Since T cells respond to processed 
antigens when recognised in the context of HLA class I molecules, autologous antigen-
presenting macrophages were included in wells to provide appropriate HLA-matched 
antigenic stimulation to T cells. 
3.2.7.3.1. Preparation of antigen-presenting cells for cloning 
Autologous PBMC were placed at 5x106/ml (lm1lwell) in RPMI (Gibco™) in 24-well 
plastic plates (Nunc) to allow monocytes to adhere (Kanof et al., 1994). After 90 minutes 
of culture at 37°C with 5% C02, wells containing adherent cells were washed 3 times with 
warmed (37°C) 10% Human AB serum in RPM! supplemented with 50U penicillinlml, 
50mg streptomycinlml, and 50mg glutamine/ml (Gibco™)] to remove non-adherent cells. 
The adherent monocytes were pulsed with the HIV Gag peptides (fmal concentration 
2ug/ml in 500ul) for 3 hours at 37°C and 5% C02. The mv Gag peptide-pulsed 
macrophages were detached using a rubber scraper and were transferred to a sterile 50ml 
culture flask. The wells were then washed with 500ul 10% Human AB serum in RPMI and 
were scraped a second time with the rubber scraper to detach residual macrophages from 
the wells. The macrophages were counted manually (section 2.2.3) and were adjusted. to a 
volume of 1 x 105 cellslml and 5x 1 03 cells were added per well. These were irradiated at 
4000 rads and added to the plated. PBMC and MMC to allow cloning in the continual 
presence ofHIV Gag peptides. 
3.2.7.3.2. Preparation of feeder cells for cloning 
When generating antigen-presenting cells for cloning, autologous non-adherent monocytes 
were collected during the various washing steps to serve as feeder cells. The non-adherent 
monocytes were counted manually (Section 2.2.3) and adjusted to lxl06 cells/ml. The cells 
were irradiated at 4000 rads and added to the wells at 5xl04cells/well. Wells containing 
feeder cells alone were also plated to ensure that the irradiated feeder cells were not 
capable of replication in culture. 
3.2.7.3.3. General culture conditions 
MMC and CD3+ T cell-enriched PBMC were plated at 0.1,0.3 and 1 cell/well respectively 
in the presence of HIV Gag-pulsed macrophages (5xI03cells/well), feeder cells 
(5xl04cells/well) and a final concentration of 100U recombinant human IL-2/well. The 
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plates were kept at 37°C with 5% CO2 to allow expansion of HIV Gag-specific T cells. 
Being careful not to disrupt the cell pellet, fresh culture media [10% Human AB serum in 
RPMI supplemented with 50U penicillin/ml, 50mg streptomycin/mI, 50mg glutamine/mI 
(Gibco™) and O.SmglmI FunginTM (lnvivoGen)] supplemented with IL-2 (for a final 
concentration of 100U/well) was added every second day by replacing half the volume in 
each well. Wells were visually inspected for clusters of proliferating T cells using an 
Olympus-CKX31 inverted microscope. At a minimum of 14 days of culture, wells with 
clear signs of proliferation were picked for further culture in the presence of a single pool 
of 66 HIV Gag peptides for a further 14 days. 
Cells were counted every 14 days (section 2.2.3). Once the cell number exceeded 
2x105/well in a 96-well plate, the cells were centrifuged at 425xG (1500rpm using a 
Heraeus 1.0R Megafuge) for 5 minutes. The cell pellet was resuspended in 500ul culture 
media [10% Human AB serum in RPMI supplemented with 50U penicillin/mI, 50mg 
streptomycin/mI, 50mg glutamine/mI (Gibco™) and O.SmglmI FunginTM (InvivoGen)] and 
was transferred to wells of 24-well plates (Nunc). Once the cell number in the wells of the 
24-well plates (Nunc) exceeded 1x106cells/well, the cells were split into 2 wells. 
Cells were maintained in culture until a yield sufficient to conduct functional analysis was 
achieved (~3.5x1 OS cells for HIV Gag pool ELISpot; :::2xl06 cells for TCR ~-typing). After 
4 weeks of culture in the presence of a single pool of HIV Gag peptides, cells were then 
cultured in the presence of anti-CD3 monoclonal antibody (Section 3.2.3) for a further 4 
weeks. The cells were cultured in this fashion for a maximum of 19 weeks and were 
phenotypically and functionally analysed by flow cytometry. 
3.2.S. Functional analysis of cervical and peripberal T cells 
3.2.S.1. Flow cytometric analysis of T cell phenotype and function 
3.2.S.1.1. Phenotypic screening of T cells 
Cells in culture were counted manually by removing lOuI of cells per well and staining 
with 10ul Trypan Blue (Section 2.2.3). Cells from wells exhibiting growth in the presence 
of HI V Gag peptides were assessed for cell surface phenotype using FACS. A volume of 
50u1 cells was combined with 5ul CD3-APC and 5ul CDS-FITC (BD Pharmingen) to 
identify CD3+CDS+ T cell popUlations and CD4+ T cell populations (CD3+CDS- T cell 
populations). The cells were kept on ice for 20 minutes to allow the monoclonal antibodies 
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to bind to cell surface markers. The cells were washed in a volume of 2ml RIO [10% FCS 
(Delta Bioproducts) in PBS (Gibco™)] and were centrifuged at 425xG (1500rpm Heraeus 
l.OR Megafuge) for 5min. The pellets were resuspended in IOOul RIO and IOOul 
paraformaldehyde (CellFix, BD Pharmingen) to fix the cells for acquisition of the data on a 
F ACScalibur flow cytometer (Becton Dickinson) and analysis using Cell Quest software 
(Becton Dickinson). 
3.2.8.1.2. Assessment of HIV -specificity by intracellular cytokine 
staining 
T cells were assayed for specificity to a single pool of 66 HIV Gag peptides after T cell 
cloning by limiting dilution. T cell clones (50ul/well) and were stimulated for four hours at 
37°C 5% CO2 with phorbol myristate acetate (PMA) (lug/ml)/ionomycin (50ug/ml) or with 
a single pool of 66 HIV Gag peptides (at a final concentration of 2ug/ml) for antigen-
specific stimulation. Brefeldin A (at a final concentration of IOug/ml) was added after the 
first hour of stimulation to inhibit cytokine secretion. Unstimulated cells served as negative 
controls for cytokine secretion. These were also incubated for four hours at 37°C and 5% 
CO2 and were also treated with Brefeldin A one hour into the incubation period. The cells 
were then washed once and were resuspended in 500ul CytofixiCytoperm (BD Biosciences 
Pharmingen). The cells were kept in the dark at room temperature for 10 minutes to allow 
for fixing and permeabilization of cells. The cells were washed once with permeabilization 
solution [0.1% Saponin (Sigma) + 1% FCS (Delta Bioproducts) + 0.01% NaN3 in PBS 
(Gibco™)]. It is important to include saponin in these wash steps to maintain permeability 
of the cell membrane as this is reversible. The fixed cell pellet was resuspended in a 
volume 5ul each of the antibodies IFN-y-PE, CD3-APC, CDS-PeCy5 and CD57-FITC to 
identify CDS+ and CD4+ T cell populations (CD3+) capable of HIV-specific IFN-y 
secretion, and to further defme their differentiation status. All antibodies were from Becton 
Dickenson. The cells were kept on ice for 30min to allow antibody binding to celJular 
markers. The cells were washed in once in 2ml permeabilization buffer and once with 2ml 
wash buffer at 425xG (l500rpm Heraeus l.OR Megafuge) for 5min to remove excess 
antibody. A volume of 500ul CellFix™ (BD Biosciences) was added to the pellets to fix the 
cells for acquisition of data on the F ACScalibur flow cytometer (Beckton Dickinson) and 
for analysis using either CellQuest software (Becton Dickinson) or FlowJo (TreeStar). 
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3.2.8.2. Assessment of HIV Gag-specificity of T cell clones by IFN-
"( Pool ELISpot analysis 
Once the T cell clones reached >3.5x105 cells (enough to conduct an IFN-y ELISpot assay 
as well as continue culturing), rhIL-2 was removed from the clones by washing and clones 
were transferred into fresh culture media containing no IL2 [10% Human AB serum in 
RPMI supplemented with 50U penicillin/mI, 50mg streptomycin/mI, 50mg glutamine/mI 
(Gibco™) and 0.8mg/mI Fungin™ (InvivoGen)]. The clones were rested out of IL2 in this 
way for 48 hours before assessment for IFN-y production by cultured ELISpot. The T cell 
clones were assayed for specificity to the five HIV Gag peptide pools according to the 
protocol outlined in Section 2.2.7. T cell clones (lx106/mI; 5x104/well) were added to the 
wells of the ELISpot plate and the net IFN-y response to the HIV Gag peptide pools was 
presented as SFU 11 06 T cells. 
3.2.9. Statistical analysis 
Medians were compared using the nonparametric Mann-Whitney test. Correlations 
between variables were determined using the nonparametric Spearman rank correlation 
test. Associations between variables in different groups were determined by two- factor 
ANOV A test. P-values less than 0.05 were considered significant. Data analysis was 
conducted using Microsoft® Excel Analysis ToolPak. and Prism (version 2.0b, GraphPad 
Software, San Diego, CA) statistical software. 
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3.3.1. Direct ex ).-iJ-o detection or HI V-I C;II,!.-specilic T cell 
responses in blood and 111 the ce rvix 
in it ially im-cstig<ltcd whether HIV Gag-spedfie T cell responses could be dctecttd 
immediotcly lifter isolation (a ,>;''0) Ilt !he eer. ix IilIld in "'ood. Intmcellular q1o\;ine 
staining and flov. e}10mc:try was used 10 examine the u "/1'0 phenotypic and functional 
plUJlCnies ofblood- and CeT\ ix-delh-ed T cells isolated from IIIV·infe<:ttd women. Figure 
).3.1 sho"1I a repre5CIltllli\e intnu:cllular e)1o\;ine l"\"SJlOOS<' dcte<:tcd by fACS following 
stimulation of eer.·ieal and blood-derh-ed mononuc lear cell$. In this doool a rlCt IIiV Gag-
sp:dlie IFN·., ~ponsc ofO.S)~'. "as OOso:r.'td in tli<.' ccr.-ix and 0.45·'0 in tile blood (net 
IFN-l responses lit defined as response5 10 Gag following subtl1lCrion of respoIlS!:s 
"hhout stimulation: Figure 3.3.1). 
Althou~ lIIV·specifk T eell responses .... ·ere detectable at the eCl"\ix direct n \';\'/). the 
number of CD) - T cells iso lated from the ~er.-ix "'"llS limiting and only Orlc functiQl1ul assII)' 
CQuid be performed peT donor. l"hi5 conlinns thot expansion o f cerviCII I T cells is 1l(Ce$S4f)' 
for more extensive invcMigation of HI V-specific T cell function at the genital muc:oSll. 
8100t l Cervix 
Figure 3.3.1. Ex ,';\"0 ulIlfjls of l'U:-' l C· ~nd een 'il-dnh'w T fells from • 
~prt'Sentflth'r IUV.infeel~d \\'omfln \\"ho hfld drl«t.blc r l'!l P01l5n to IIIV Ga g. 
IntlUCelluw C)1f)\r;inc staining W3lI used to investigu.le IFN""1 ~ponses to a single pool of 
66 HIV Gag pqJlklcs in pm.lc· and cervix-<leri\·ed T cells isolated from HIV-infected 
women. TIle T cells "c~ stimulaled with lile sinl!1e pool of66 /11V Gag pcptides. 01 were 
left unslimuiated for a period of 5 OOUIS, Ill1d were slained with CDJ-APC, CDS-PeCY5, 
and IFN-l-PE. The proponion of IFN""SCCIClillg CD4- and CDS' T ce lls was determined 
by elUlmining IFN-., cxpre.-siOll in the CD) population. A ne/ IIiV -specific IFN.,. response: 
ofO.S)". was obsef\cd in cervical CDS' T cells. IUl<J 0.450/. in blood-d~rivcd CDS~ T cells. 
Analy51s " .... p<ri"<>nIlM a,ing FlowJ., (~indty prm·,ded II) TrttStar). 
" 
3.3.2. Ilolyclonal expa nsion of' een'ica l T cells 
Nine .... omen from a cohort of 35 ..... ith high frequcllCics of H1V-~peeifie T cells in blood 
WI.'TC idemified in Ch:tpter 2 (Table 2.3.3) and included in the study. PBMC and cervical 
C}10brush-deri"ed mucosal mononuclear cells (MMC) were isolated from each of these 
women. A mcan ± SO of6.49 x lO! .to 5.38xlO' (range 1.00 x 10' - 1.87xIO~) T cells ..... as 
rcrowred from the cer .. ieal e)10brushcs of mcsc 9 women. The viability and cervical 
lymphoc)1e coums of the 9 women al\' ilIustratl-d in Table 3.3.1. 
Table 3.J.1. Chlll1lflenSlics of ee .... ·jeal ~·lOhrush specimens isolatfd from 9 " !lmcn 
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Cervical Teens isolated from the 9 Il IY·infected women ..... ere pol)'clonally exp.rndcd in 
me presence of anti·CD3 monoclonal antibody for 14 days and with HIY Gag peptides for 
14 days to expand mv Gag-specific T cells. Figure 3.3.2 depicts the kinetics of cervical T 
cell expansion during culture. Cervical MMC from 2/9 (22.2"_) o f donors did not expand 
aftcr 28 days (Figure 3.3.2). However. the majority of samples (119; 11.8%) increased in 
number during culture, with a mean of I 54-fold expansion (runj,'C 1.33-fold - 93-fold; n=7; 
Figure 3.3.2) alld a l1lI.'all count of 1.0Sx 106 ± 8.0x 10' c"lIs after 28 dllys in cuhur.'. 
After the 28-doy polyclonal ;/1 "itro expansion period. cervical MMCs were ussesS(.-d. for 
lilY Gag pool-s pecific [FN-l respolt5<-'S by IFN--y ELlSpo! immedilltcl ), prior to T cell 
cloning by limiting dilution in one of these 9 donors (FiJ,'Ure 3.J.3). This representat ive 
donor's cervical T cells respolldcd to", of the 5 HIV Gag pools tested , wim Pool 3 (Gag 
peptidcs 29 to 42; corrcspollding to p24; Chapler 2; Figure 2.2.3) being the most 
immunodominant region largeted at the cervix in this donor. The 
cer.·leal MMC's did not respond to peptidcs in Pool 2. I n comparison, PBMC derived from 
this donor showed responses 10 all 5 of the Gag pools tested. Pool J ..... as also me most 
immunodominant region of Gag targck-d in blood for this dooor. inicrestingJy, the 
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magnitude o f II'N-l responses to Gag pool I wos significamly higher at the cervix in this 
patient lilan those found in I'I3MC. The nct cumulativc IIIV Gag-specific response for th is 
donor a! this timc point "US 7860 SFUlIO~ r.1MC at the cervix comparcd to the 5936 
SI'Ul l0" I'Br>.IC del<:ctoo in the corrcsponding PBJ\'lC sample. The remaining 819 donors 
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Fi!!un' 3.3.2. (;rnwlh kindies ur rC 'Tical Ml\IC after 28 da)'s of polydon~1 upan~ ion 
"ilh anli-CD3 antibody and III V- I Gag peplides. Ccr.icol T cells isolak'd from IIIV-I-
inte.:ted women were expanded in the presence of ami-CDJ antibody for 14 days and in the 
prcscJlCe ,I f HIV - t Gag peptides for a funher t -I days. Ce", iea l r.,·IMC from each donor ".,<lS 
eounlt;'d using 11)1',,1) staining and a hocmO(:ylmnclcr at day 0 and a! day 28. 
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Figure 3.3.3. IIIV Gag llOol-s rwciflci1r of cC"' ic~l i\li\l C and 1'lJi\lC fronl a 
l1"pN'scnl~liH llonor NY2.n ;offl'r in "if'" polyclunal cxp~ns ion. Cc..,.ica l MMC and 
PUI\1C wen: pol)clonall) c.xpandl-d for 14 days in the pr.:sencc of ami-CDJ monoclonal 
an tibody ami for a lunhc'r 14 days in the presence of Ii single pool of HIV Gag peplidl'S to 
pmnlott' Ihe growth of IIlV Oag-spcdfic T ce lls. (A) C<,nical MMC ""en' pla!<'d ;nlo 
triplicate "ells a1 50000 cells/well .... hil .. 1'Il/l.IC .... ere platl..:l al l00(lO() cells! \\ell in 
triplicate. The cells \\e ..... stimulated with S IIIV-l Gag peptide pools (final concenlrmion 
2uglml). Nel respons.'s greater than 100 SFUlI O~ cells were considered posi live responses. 
(II ) Bar graph o f nel n·""N-l respon5es J1"f pool of I' (JMC and polyclonaUy expanded 
cervical MMC of donor NY233. 
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3.3.3. Limiting dilution cloning of HI V-I Gag-specific 
IJOMC· lind ccr\'ix-deril'ed T cells 
Tabl~ 33.2 sununariZi:s the cloning ellicierlC) for IIIV-sJ>C'Cilie cervical and blood-dt:ril"l:d 
cd ls. Eil:hL OUI of Ih" ninl." donors I."xaminoo ) icldcd wells with positi,'c gro"lh during the 
14 day elonlll& pl."riod. For bolh eervi ~ and PBMC doning expcrimcDls. the e~p<"'Ctcd 
pkking r~qucnq cxn"t!dl.'d lhe aClual nwnbcr of wells pid:oo (Table 3.3.3) indicating that 
oot t:\'~'1) cell plat .. '\! expanded succ .. ss full), Generall) . the picking freqllCncy for cervical 
and blood-ded\' .. ", 'I cells at lhis sLaJli! was oot srgni licaml) different \ 11 2"/. o ftOlal prntoo 
for '''T' ieol clont's 'Omp.1rl'\!tO 13 _ 1 ~. for blood c lones: p=O.J73 . .-\~. tcsl). 
Tahll' 3.,\ ,2. Oh~('t"\('d T c('11 d oninlt ('m d enl.") of cU"'ical anti h lood-tl crind cclb h~ 
limit in lt dilution 
-""-~ PI.oU"II • _ 
Do"", Fr!qU .... r' "Ic~'" _' t'li.! I'IckH _ . t'li.! 
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•  ,
• • , 
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Where ' d"'1lOk'S the frequcne~ at which c;:lIs "ere plated peT 100111 well; and ~ the IICh~,1 
number of wells picked from wells containing cervlx- lind blood-derin-d T ,ells 
~~tiwly. TIl<- mble represents oil "ells picked and plmed when cloning by limiting 
dilution al I.'a,h \ isil . Donor NY233 is absent ~s no blood ~nd C<Tvicul C) tobrush samples 
"~n: picted from thiS donor. 
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T.bll' 3 .• \.3. Compariw n IIr E:\p«ted and '\1'111111 picking rrcqll~nci ..... o( cen ix· and 
I' BMC·dtril t d T ct li s du ring doning b, lim ilin!: dilu lion 
Expec!!d Ff!9uency 
o 1!We1l (10"401 wells plaled) 
o 3twe1l P3 33'" of wells plahld) 
Ilwell (100% of weu, plated) 
ActUilI Freg~ency ('II.) 
552 t 003 
16.7 t 006 
4, O.t 017 
PBMC 
6.67 i 0 05 
3&9t003 
150:1; 025 
3.3A. FUllctional analysis of PBMC- and ccr"h:-dcri\'l'd T cell 
clones 
From tht:- 74 bJood.derin:d and 51 ttrd_~.derhed T cdl dones picked. signincllntl) more 
of !he blood.derilcd clone!! CORllXlred II ilh me fer-. ieal T cell clones 112/74 \ 16 ,2~.) blood 
and 2<51 (3.9"1.) cenical clones) ",ere spccinc for IIIV Gag b} EUSpol and IFN·y [eS 
{ Iabk 3.3.4: p=(I.0528;.\': leSI,. 130m oflhl." c{'r-.ical T cell cJoo..>s and 1 f)I3MC 1'[0111' Ihal 
sOO"'-N f flV ·spe<:i neily 'Iere dl."ril cd from the sam .. donor (NY t 30 I. This particip.,nt lind 
a C04 rollnl of 322 cells/ul and II I irul I,-,ad of 39i!: II .:11 this I isi!. She ""lis also Ihe second 
SlfQllgesl Gag responder from Ihe cohort of 35 (Chapter 2: Figure 2.3.4) lhal W!ill 
im<'Sligawd "ith a cumulalive nel response maglli llide of 8267 Sf1J/]O' cells III Ihe visit 
illlmcd imd)' prior 10 tOC one uSl-d in th is cloning c~p<'rimcn1 . 
--,- .. 1 110 012 .. 
Of thl." 12174 blood.derhed T e .. lI s d.mcs d",l were found to be II IV·spceinc. Ihl." 
s)l\:cilic)l~ of th .. lll,:UorilY (1 1/ 12) was confimled b} IFN.-y FLlSpol whi le 1/ 12 ""s 
00I11innoo b> II'N·y ICS. I') gun: 3.3,4 shows II repreSl'nIDU\'e I:LI::'POI for 2 of theSl' clones 
(NY094 done 5 and 10) as we ll as ;I SUmlll.1ry of nel lFN·y responses in tOC clon~s 
ass .. "sed. 
FACS phenOl> pic anal) sis of62174 blood and 40/51 cer-.ical dones picked idenlined those 
picked clOOi.'s as cor T etll.s (data nvl shown). Of me 62 blood dOl1l:s that were 
phenolypOO 36/62 (58~") "'ere ~·~elllsil .. l> C08' C03' T cells and 19'62 (30-. ) ([).I · CO)' 
T l"t:lIs (dma flOl shown). Ofml" 40 ttr .. ical clones lh:lt were phenolypcd. 29140 (n.s-,., 
"'·er .. I."xcfusII·d) (08 'C03 ' T l·l."lIs and 11/40 (27.5 'l'o ) C[)..ITD3' T cells IdaCl flOl 
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}' igun' J.3.~ . IIIV Gag-5pccifiti l,' of cc,...·iI'MI ~JJd puipln"r lll T cell d onl"li (A) A 
represenlati. e example of the ELiSpot plale result of 2 of Ihe 10 dooors assayed for lilY 
Gog-speci fic IFN-y secretion. Tll", cells wen: platoo in dUplicate wells orSx l 0~ cell,",wcU 
and wen: .1;",ul01oo wilh " single pool of I nv GBg pcplidcs (Iinll l conc<'nlrtll;On ~uglml). 
BOl li clones responded \0 the II IV Gog pcplidc pool. wells A lind B. (8 ) The net J IIV Gag-
specific lFN-l' responscs of the 12 PBMC-dcri'l-d T ce ll dones. and (C) the 2 cervix-
derived T cdl clones Iletleraled by limiting dilution cloning. IIlV Gag-specific clones 
NY13OCA. NYIJOC.S. and NY130P.IO wcrc identified by leS. The nel pt"'~nt3ge of 
lhese I IIV-srcific IfN-y secreting T cell clones was normalised to nel IIIV-specific T ce ll 
clones/hIO . The remain ing II 1I1V-speci/ic T cell clones ",en: iden tified by If N-y 
EU Spot. On!) m Y-specific lFN..,. responses grealer than 100 SFUIlO· cells were 
considcrcd posilive responses. 
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3.3.5. 100'esligalion of malurational stili us of cervix- lind 
1}8MC-derh'cd T cell clones 
Nont" of the 51 cervical T cell clones pid;:ed during limi ting dilution ~uhun: c~p~nd~'(j 
c:noush durinJ.\ In rUm culrure to facilitale IFN-., EU Spol anal)sis of HIV Gag·speci ficity. 
11.- cervi:-:..(]eriwd T cell clones wen: cuhured for a mean period of 12.8 weds and 
PI\M(' .. lr:ri\'M T <,<,-II e~ for" "",ao l"'rioo o r I H~ .... "",h of " " Imre Ik'<"I111 ;;oo ('4~r"i"l1l 
T cells "'"Cit' dc:ri u:d from genilul llSl>ut and there fore wcre li l ely to be effector ce lls while 
blooJ !lenved cdls "'"Cn: obtainc:d from the circulat ing T cd l pool. it ..... as of inlerest 10 
in\estigate the respect;"c m:u urutiona l statUS of doncs dcrh'cd from each si te, This srudy 
focused on expres)ion orCDS7 on clollC'S fmrn blood and cervix becauSe this maturational 
markcr has previously bet:n linked to [cmlinal differentiat ion and ~neSC('no;e (clonal 
exhaustion; Ilrenchlcy tI ai, 2(03), To explore the possibili ty of T cell exhaustion as a 
factor underl),ing Ihe difficulty in gencrnting IIIV·specific clones from cervical tissue,!he 
expressio n of CDS? was in\'estigalCd in matched cervix- and blood-deTi\'Cd T cells isolated 
d i~tl)' ex I'i.'o (n=8: figure 3J,6,A) and in T ccll ciol'K.'S derh'ed from both compartments 
(n-40 and .17 matched cervix- and blood-<krin'd clones respectively: Figure 3.3,6.8), 
Firsily.icveisof CDS7 on CD3' T ce l1s ..... as oot significan!l) different in the blood of HIV 
negali \'e individuals. and the blood and ceTvi~al ~ples from chronically IIIV-infe<:ted 
women (Figure 3.3.6 A), ~condl). 00 signirICant difference was obsen:ed in COS7 
expression belween blood and ccrvical r cells directl) ex I'n'(l {Figure 3.3,6.A}. lJu~ CD5? 
expression .... -as significantly higher in CCT\ leal clones than blood clonc:s cultured for simi lar 
periods of lior (~igure 3.3.6. 11: P<0,0Q(1). h n hermon:, CDS? exprc5!'lion was 
significantl) higher in cervica l T cell clones than ccr.icaJ T ce lls a.sscsscd diredl) ex 1';1'0 
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Figure 3.3.5. CDS7 nprcs~ ion or blood- lind cC I"\' ix-d erh'cd T ceU d on(,5 and U !'il'O T 
cells. I'I3MC· lmd ccrvix-dcrivcd T cells from H!V.i nf~'Cted donors were analysed dim:( ex 
"il'Q or after periods of cloning by limiliog dilution for c~prcs~ion of the T ce ll exhaustion 
marker CD57. The T ceUs were Sl im\l l n!~'d wilh u single pool of 66 ! Il V Gag peptide:>. or 
wen: left un~limulul~-d lor a period of 5 hours, and we..., stained wilh CD3·APC. CDS-
pecy~. CDj7·F1TC and TI'N·l·PE. (A) CO:H cXpn.'ssion b}' CD3' T c .. lls in IIlV. PBMC 
( n~9) and dil'\.'Cl ex \"{\'O lIlV' cervical T cdls (n=8) and PBMC (0=8) arc illuscr.u~-d. No 
sigJIiliCllm ditlcrcl>Cc in CDS7 expression is ohscr\'oo bctv.'I."-'1'1 tile groups. (B) CD57 
cxprt:ssion by CDJ ' cerviclLi T cell clon~-:> (menn 12.8 W~~~5 ofculturc) WIlS significa/ltly 
grcater than CD57 expression by PI3f-1C--dcri\"cd T cdl clones (mean 13.S weeks of 
culture). The proportion or lilY Gag-specific COJ-CDS ' T cells was determined by 
examining lFN-y expression ill the CD) popu1;'lion. 
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Chapter 3 
Generation and characterization of HIV Gag-specific 





A key factor limiting extensive studies of HIV -specific T cell responses at the genital tract 
of HIV -infected women is the low yield of cervical T cells using well-tolerated sampling 
methods. Highly sensitive methods of investigating T cell function (IFN-y ELISpot, 
intracellular flow cytometry, MHC-peptide tetramer staining, SlCr release assays to name a 
few) require cell numbers considerably greater than the lxl04 cells commonly recovered ex 
vivo from a cervix cervical cytobrush. To circumvent the problem of low T cell recovery in 
this project, I expanded cervical T cells both polyclonally and by limiting dilution cloning 
to allow more comprehensive investigations of HlV -specific T cell phenotype and function 
at the cervix. Using 9 women with well characterized and high magnitude T cell responses 
to HIV Gag, I showed that T cell clones from the peripheral blood and cervix that were 
specific for Gag could be generated. All of the clones characterized were of a CD8+CD3+ 
T cell phenotype. Only a minority of the clones picked from the cervix and blood produced 
IFN-y in response to Gag. Most importantly, I showed that the efficacy of generating Gag-
specific T cell clones was far lower in cervical samples than in blood. Others in our 
laboratory have shown that cervical T cells have significantly higher frequencies of Gag-
responsive cells than blood-derived T cells (p=0.0002; Pamela Gumbi, Manuscript in 
preparation) and that cervical T cells exhibit significantly higher frequencies of responses 
to PMAlionomycin than blood T cells (indicating heightened activation status and viability, 
Pamela Gumbi, personal communication). The poor efficacy of generating cervical T cell 
clones in this study was therefore unlikely to be due to poor viability or low Gag-specific T 
cell frequencies in cervical samples but may be due to poor in vitro proliferative capacity of 
cervical-derived T cell clones compared to blood clones. I went on to detennine the 
maturational status of the cervical and blood T cell clones generated in this study using the 
tenninal differentiation or exhaustion marker CD57 (Brenchley et ai., 2003). I showed that 
while ex vivo cervical and blood T cells show similar levels of CD57 expression, cervical T 
cell clones showed significantly higher levels of this marker compared to blood-derived T 
cell clones despite similar time in culture. 
The nine chronically HIV -infected women used for this study were selected from a cohort 
of35 based on high magnitude and breadth ofIFN-y T cell responses to HIV Gag (Chapter 
2). The motivation for using high HIV-specific IFN-y responses in blood as a predictor of 
HIV -specific T cell frequency at the cervix was underscored by a recent report of 
similarities in HIV Gag-specific epitope targeting between the blood and mucosa of the 
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same individuals (Musey et al., 2003) indicating some link between immunological 
compartments. 
Although ex vivo F ACS analysis clearly has the capacity to detect HIV -specific T cell 
responses at the cervix and blood as I have shown in this chapter, the number of CD3+ T 
cells isolated from the cervix remains a significantly limiting factor. One of the major 
advantages of direct ex vivo cytokine flow cytometry is the ability to study co-expression of 
cytokines on single cells without any potential artefacts induced during long term culture. 
However, when cell numbers are insufficient to conduct a comprehensive analysis of cell 
function as a result of low yield of cervical T cells, in vitro expansion of T cells is essential. 
I next investigated HIV -specificity in cervical mononuclear cells after polyclonal in vitro 
expansion to determine whether HIV -specific T cell responses could be detected after 
culture in mucosal specimens. Cervical MMC were expanded in the presence of anti-CD3 
monoclonal antibody for 14 days and for a further 14 days in the presence of HIV Gag 
peptides. Cervical MMC from the majority of HIV -infected donors (7/9 donors) increased 
in number after culturing (median 1.54-fold increase; range 1.33-fold - 93-fold; n=7) 
yielding a mean count of 1.05x106 (± 8.0x105) MMC after 28 days in culture. Similar HIV 
Gag pools were targeted in the expanded cervical MMC and PBMC samples. From these 
limited studies, I noticed a broader response in blood than in expanded cervical MMC. HN 
specificity could therefore be detected after in vitro culture of the mucosal T cells. 
Finally, the main objective of this study was to generate matched cervical and blood-
derived T cell clones by limiting dilution to compare HIV -specific T cell responses 
between the blood and the genital mucosa at the clonal level. HIV Gag-specificity was 
observed in 12174 blood-derived clones and in 2/51 cervix-derived T cell clones. Although 
I clearly demonstrated in this chapter that HIV Gag-specific T cell clones could be 
generated from both the blood and the cervix of chronically HIV -infected women, I 
consistently found that the cervical MMC clones were generated at significantly lower 
frequencies than the blood clones and expanded less successfully in culture. 
Because of the expansion kinetic differences to Gag that I noted in the blood- and cervix-
derived T cell clones, I went on to investigate potential factors contributing to slow in vitro 
growth of cervical clones. I focused on expression of the exhaustion marker CD57. CD57 
expression was significantly greater on cervical T cell clones than blood-derived T cell 
clones. CD57 expression was not significantly different between blood- and cervix-derived 
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T cells isolated direct ex vivo, and when compared to CDS7 expression of PBMC from 
HIV -seronegative donors. CDS7 expression was only significantly upregulated on cervical 
T cell clones compared to cervical T cells assayed direct ex vivo, but not between blood-
derived T cells assayed direct ex vivo and blood-derived T cell clones. It is likely that in 
vitro expansion of cervical MMC during limiting dilution cloning selected for the 
expansion of a particular subset of memory cells close to maturity that were not detected by 
F ACS directly ex vivo. It is clear that further investigation into T cell proliferative and 
functional impairment is necessary to improve the efficiency of the generation of HIV-
specific T cell clones by limiting dilution in order to determine if compartmentalisation of 





Mucosal immunity has a fundamental role in controlling HIV-l infection. However, 
advances in the understanding of HIV -specific cellular immune responses at the site of 
transmission in women, the genital mucosa, has been hampered primarily by the recovery 
of insufficient viable T cells by non-invasive procedures. In the present study this problem 
was circumvented by sampling from the cervical transformation zone of the female genital 
tract where T cells are more abundant (Pudney et at., 2005), and expanding the HIV-
specific T cell populations isolated from cervical cytobrush specimens. 
In this study, HIV -1 Gag-specific T cell responses in blood sampled from 35 chronically 
HIV -infected women were assessed for IFN -y responses to pools of peptides spanning the 
entire HIV-l subtype C Gag protein (Chapter 2). Nine women with the highest frequencies 
of HIV -1 subtype C Gag-specific T cells were selected for T cell cloning experiments. T 
cell IFN-y responses against Gag were common in these chronically HIV -infected women 
with 33/35 (94.3%) women having clear specificity against Gag. These responses, in 
accordance with previous reports (Buseyne et at., 1992; Masemola et at., 2002 Kiepiela et 
at., 2007), were focused predominantly against the capsid protein p24, which is recognized 
to be the most conserved of Gag (Buseyne et at., 1992). Furthermore, the women in the 
cohort were more likely to respond to only 2 of the 5 HIV Gag pools, with the targeting of 
p 15 (pools 4 and 5) increasing in frequency with increasing number of pools targeted. No 
association was observed between either the magnitude of responses or the number of pools 
targeted and vira1load as previously reported (Masemola et at., 2004; Addo et at., 2003; 
Edwards et at., 2002). This was likely to be result of the limited cohort size used in this 
study (Kiepie1a et at., 2007) as well as the fact that only IFN-y production by CD8+ T cells 
was investigated (Betts et at., 2006). Betts et at. (2006) reported that measurement ofIFN-
y production alone is insufficient to control viremia but instead the ability of CTL to be 
multifunctional is associated with better control of viral replication. Recently, Kiepiela et 
at. (2007) clearly showed using measurement of IFN-y alone that CTL specifically 
recognizing Gag were capable of reducing viremia but only when the cohort exceeded 400 
individuals indicating the need for significantly increased populations to make this sort of 
association. 
I show in this study that cervical T cells from HIV -infected women can be expanded both 
polyclonally and at the clonal level to allow more comprehensive investigations of HIV-
specific T cell phenotype and function at the cervix (Chapter 3). Using 9 women with well 
characterized and high magnitude PBMC responses to HIV Gag, I showed that T cell 
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clones from the peripheral blood and cervix that were specific for Gag could be generated. 
All of the clones characterized were of a CD8+CD3+ T cell phenotype. However, only a 
minority of the clones picked from the cervix and blood produced IFN-y in response to 
Gag. It is therefore possible that the consensus HIV Gag subtype C sequence used in this 
study, designed from data predominantly accumulated from studies in blood, may fail to 
elicit specific responses at the cervix. Since there is currently no evidence that HIV variants 
differ at key epitopes between blood and mucosal tissues it would be beneficial to compare 
HIV epitope-specific T cell responses between the two anatomically distinct compartments. 
However, considering that the yield of mucosal T cells is the limiting factor in pursuing 
this sort of investigation, and that in this study cervical MMC clones were consistently 
generated at significantly lower frequencies than the blood clones and expanded less 
successfully in culture I investigated potential factors contributing to slow in vitro growth 
of cervical clones. 
The importance of understanding and identifying factors associated with the lack of T cell 
proliferation has been underscored by the recent finding that upregulation of the inhibitory 
receptor PD-1 (programmed cell death 1) on the surface of HIV -specific CD8+ T cells is 
associated with T cell exhaustion and disease progression (Day et al., 2006). Furthermore, 
the observation that the blockade of signalling pathway of PD-1 and its ligand PD-L1 
results in enhanced HIV -specific CD4+ and CD8+ T cell function (Freeman et al., 2006; 
Trautman et al., 2006) highlighted the need to investigate the renewal of a functionally 
competent HN -specific T cell repertoire in an attempt to prevent disease progression. I 
focused on the expression of the maturation and exhaustion marker CD57. CD57 
expression on CD8+ and CD4+ T cells has been associated with a lack of proliferative 
capacity and with chronic immune activation (Brenchley et al., 2003; Palmer et al., 2005). 
Furthermore, an increase in CD8+CD57+ T cell number is frequently associated with 
persistent viral infections (Weekes et al., 1999; Wang et al., 1993), with these cells 
displaying a clear propensity for activation-induced apoptosis (Brenchley et al., 2003). In 
this study, CD57 expression was significantly greater on cervical T cell clones than blood-
derived T cell clones. CD57 expression was not significantly different between blood- and 
cervix-derived T cells isolated direct ex vivo, and when compared to CDS7 expression of 
PBMC from HIV -seronegative donors. CD57 expression was only significantly 
upregulated on cervical T cell clones compared to cervical T cells assayed direct ex vivo, 
but not between blood-derived T cells assayed direct ex vivo and blood-derived T cell 
clones. It is likely that the difference in CD57 expression observed between the blood and 
cervix was as a result of differences in manipulation in vitro i.e. the initial polyclonal 
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expansion of cervix-derived but not blood-derived T cells before limiting dilution cloning. 
Furthermore, the in vitro expansion of cervical MMC during limiting dilution cloning 
selected for the expansion of a particular subset of memory cells close to maturity that were 
not present at high frequencies ex vivo. An increased level of CD57 expression on CDS+ T 
cells at the cervix is indicative of increased immune cell replicative exhaustion at the site of 
transmission of HIV. Replicative senescence of CTLs has recently been associated with 
impairment oflytic and cytokine functions in HIV infection (Dagarag et al., 2003; Yang et 
al., 2005). Since perforin expression and proliferative capacity are associated with long-
term nonprogression in HIV-l-infected individuals (Migueles et al., 2002), the loss ofCTL 
killing potential with replicative senescence raises concern about the effectiveness of 
cellular immunity at the female genital tract. 
This is the first study to have investigated CD57 expression of cervix-derived T cells under 
conditions of clonal expansion and has important implications for mucosal vaccine design. 
The ability to mount a sustainable and effective mucosal cellular immune response to an 
HIV vaccine is one of the fundamental prerequisites to providing prophylactic protection 
against infection. This study has demonstrated that clonally expanded cervix-derived 
mucosal T cells directed against HIV Gag express significantly higher levels of CD 57 than 
similarly clonally expanded blood-derived cells. Further investigation is needed to 
determine whether this is related to the fact that these mucosal cells were derived from 
women with chronic HIV infection, and is therefore related to the disease status of the 
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